{"docstore/data": {"d7c8fdab-09be-4f44-8b48-7097025cbefe": {"__data__": {"id_": "d7c8fdab-09be-4f44-8b48-7097025cbefe", "embedding": null, "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0aedb42c-40a9-4e23-ae4d-6349762fd4ae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "92486ec2216885e22e4cacde9d5724924e4e89480d0e52ef2ff63b97c2b7ba3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d66aba3-781b-4f65-9789-4c0d52d205c5", "node_type": "1", "metadata": {}, "hash": "f03978817e479dc14bda6508831816c2d80b0579a782a742c8d0d5145965de34", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n1 / chap  30  \n  \n \n \nProduits  pharmaceutiques  \n \nNotes.  \n1. - Le pr\u00e9sent  Chapitre  ne comprend  pas : \na) les aliments di\u00e9t\u00e9tiques, aliments enrichis, aliments pour diab\u00e9tiques, compl\u00e9ments alimentaires, boissons  \ntoniques et eaux min\u00e9rales, autres que les pr\u00e9parations nutritives administr\u00e9es par voie intraveineuse  \n(Section  IV); \nb) les produits, tels que les comprim\u00e9s, les gommes \u00e0 m\u00e2cher ou les timbres ou rondelles autocollants  \n(administr\u00e9s  par voie  percutan\u00e9e),  contenant  de la nicotine  et destin\u00e9s  \u00e0 aider  le sevrage  tabagique  \n(24.04);  \nd) les eaux  distill\u00e9es  aromatiques  et solutions  aqueuses  d\u2019huiles  essentielles,  m\u00e9dicinales  (n\u00b0 33.01);  \ne)  les pr\u00e9parations  des n\u00b0s 33.03  \u00e0 33.07,  m\u00eame  si elles  ont des propri\u00e9t\u00e9s  th\u00e9rapeutiques  ou \nprophylactiques;  \nf) les savons  et autres  produits  du n\u00b0 34.01  additionn\u00e9s  de substances  m\u00e9dicamenteuses;  \ng) les pr\u00e9parations  \u00e0 base  de pl\u00e2tre  pour  l\u2019art dentaire  (n\u00b0 34.07);  \nh) l\u2019albumine  du sang  non pr\u00e9par\u00e9e  en vue d\u2019usages  th\u00e9rapeutiques  ou prophylactiques  (n\u00b0 35.02)  ; \nij) les r\u00e9actifs  de diagnostic  du n\u00b0 38.22.  \n2. - Au sens du n\u00b0 30.02, on entend par produits immunologiques les peptides et les prot\u00e9ines (\u00e0 l\u2019exclusion des  \nproduits du n\u00b0 29.37) qui participent directement \u00e0 la r\u00e9gulation des processus immunologiques tels que les  \nanticorps  monoclonaux  (MAB),  les fragments  d\u2019anticorps,  les conjugu\u00e9s  d\u2019anticorps  et de fragments  \nd\u2019anticorps  les interleukines,  les interf\u00e9rons  (IFN),  les chimiokines,  ainsi  que certains  facteurs  \noncon\u00e9crosants (TNF), facteurs de croissance (GF), h\u00e9matopo\u00ef\u00e9tines e t facteurs de simulation de colonies  \n(CSF).  \n3. - Au sens des  n\u00b0s 30.03 et 30.04  et de la Note 4  d) du Chapitre,  on consid\u00e8re  : \na) comme  produits non  m\u00e9lang\u00e9s  : \n1) les solutions  aqueuses  de produits  non m\u00e9lang\u00e9s;  \n2) tous  les produits  des Chapitres  28 ou 29; \n3) les extraits  v\u00e9g\u00e9taux  simples  du n\u00b0 13.02,  simplement  titr\u00e9s  ou dissous  dans  un solvant  quelconque;  \nb) comme  produits m\u00e9lang\u00e9s  : \n1) les solutions  et suspensions  collo\u00efdales  (\u00e0 l\u2019exclusion  du soufre  collo\u00efdal);  \n2) les extraits  v\u00e9g\u00e9taux  obtenus  par le traitement  de m\u00e9langes  de substances  v\u00e9g\u00e9tales;  \n3) les sels et eaux  concentr\u00e9s  obtenus  par \u00e9vaporation  des eaux  min\u00e9rales  naturelles.  \n4.", "start_char_idx": 0, "end_char_idx": 2393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d66aba3-781b-4f65-9789-4c0d52d205c5": {"__data__": {"id_": "8d66aba3-781b-4f65-9789-4c0d52d205c5", "embedding": null, "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "0aedb42c-40a9-4e23-ae4d-6349762fd4ae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "92486ec2216885e22e4cacde9d5724924e4e89480d0e52ef2ff63b97c2b7ba3c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c8fdab-09be-4f44-8b48-7097025cbefe", "node_type": "1", "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "bb6e465ca999831808e8c4603723c7d1ab5da4adabe77bbdc049315e3d6a0baa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e076a90-493a-462f-a532-92b9a044b5b1", "node_type": "1", "metadata": {}, "hash": "6894d99bd9504d34340351583adb4ce35d2410352eddc3ee33abd05cb5f9f034", "class_name": "RelatedNodeInfo"}}, "text": "4. - Ne sont compris dans le n\u00b0 30.06 que les produits suivants qui devront \u00eatre class\u00e9s dans cette position et non  \ndans  une autre  position  de la Nomenclature  : \na) les catguts st\u00e9riles, les ligatures st\u00e9riles similaires pour sutures chirurgicales (y compris les fils r\u00e9sorbables  \nst\u00e9riles pour la chirurgie ou l\u2019art dentaire) et les adh\u00e9sifs st\u00e9riles pour tissus organiques utilis\u00e9s en chirurgie  \npour  refermer  les plaies;  \nb) les laminaires  st\u00e9riles;  \nc)  les h\u00e9mostatiques r\u00e9sorbables st\u00e9riles pour la chirurgie ou l\u2019art dentaire; les barri\u00e8res anti adh\u00e9rence  \nst\u00e9riles  pour  la chirurgie  ou l\u2019art dentaire, r\u00e9sorbables  ou non  ; \nd) les pr\u00e9parations  opacifiantes pour examens radiographiques,  ainsi  que les r\u00e9actifs  de diagnostic con\u00e7us  \npour \u00eatre employ\u00e9s sur le patient et qui sont des produits non m\u00e9lang\u00e9s pr\u00e9sent\u00e9s sous forme de doses ou  \nbien  des produits  m\u00e9lang\u00e9s,  constitu\u00e9s  par deux  ingr\u00e9dients  ou davantage,  propres  aux m\u00eames  usages;  \n \nChapitre  30", "start_char_idx": 2391, "end_char_idx": 3387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e076a90-493a-462f-a532-92b9a044b5b1": {"__data__": {"id_": "6e076a90-493a-462f-a532-92b9a044b5b1", "embedding": null, "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b831dd29-def8-47cb-ae7c-a20123db8836", "node_type": "4", "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "77eb3b6e39d48c9ff47f69ac8f13f9874dbb1f2356153ea4a6199b27175a9cda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d66aba3-781b-4f65-9789-4c0d52d205c5", "node_type": "1", "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "be230d9697c9c13d8a1e32ce5e5db81c394659bb365f2e9df27e393fbebb5ae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "200941cd-78f6-4e4a-9e32-ee17811558d0", "node_type": "1", "metadata": {}, "hash": "75f2e449482dc9b6c70cde61bf37e8b0d9373decf290ea32c8cee9902bcb77d4", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n2 / chap  30  \n  \n \ne) placebos  et trousses  pour  essais  cliniques  masqu\u00e9s  (ou \u00e0 double  insu),  destin\u00e9s  \u00e0 \u00eatre  utilis\u00e9s  dans  le cadre  \nd\u2019essais  cliniques  reconnus, pr\u00e9sent\u00e9s  sous  forme  de doses,  m\u00eame  contenant  des m\u00e9dicaments  actifs;  \nf) les ciments  et autres  produits  d\u2019obturation  dentaire;  les ciments  pour  la r\u00e9fection  osseuse;  \ng) les trousses  et bo\u00eetes  de pharmacie  garnies,  pour  soins  de premi\u00e8re  urgence;  \nh) les pr\u00e9parations  chimiques  contraceptives  \u00e0 base  d\u2019hormones,  d\u2019autres  produits  du n\u00b0 29.37  ou de \nspermicides  ; \nij) les pr\u00e9parations  pr\u00e9sent\u00e9es  sous  forme  de gel con\u00e7ues  pour  \u00eatre  utilis\u00e9es  en m\u00e9decine  humaine  ou \nv\u00e9t\u00e9rinaire  comme  lubrifiant  pour  certaines  parties  du corps  lors des op\u00e9rations  chirurgicales  ou des \nexamens m\u00e9dicaux  ou comme agent  de couplage  entre  le corps  et les instruments  m\u00e9dicaux  ; \nk) les d\u00e9chets pharmaceutiques, c\u2019est -\u00e0-dire les produits pharmaceutiques impropres \u00e0 leur usage initial en  \nraison, par  exemple,  du d\u00e9passement  de leur date  de p\u00e9remption  ; \nI) les appareillages identifiables de stomie, \u00e0 savoir les sacs, coup\u00e9s de forme, pour colostomie, il\u00e9ostomie et  \nurostomie  ainsi  que leurs  protecteurs  cutan\u00e9s  adh\u00e9sifs  ou plaques  frontales.  \nNote s de sous -positions  \n1.- Au sens  des n\u00b0s 3002.13  et 3002.14,  on consid\u00e8re:  \na) comme  produits  non m\u00e9lang\u00e9s,  les produits  purs,  que ces compos\u00e9s  contiennent  ou non des impurt\u00e9s;  \nb) comme  produits  m\u00e9lang\u00e9s:  \n1) les solutions  aqueuses  et les autres  solutions  des produits  du paragraphe  a) ci-dessus;  \n2) les produits  des paragraphes  a) et b)1) ci-dessus  additionnn\u00e9s  d\u2019un  stabilisant  indispensable  \u00e0 leur \nconservation  ou \u00e0 leur transport;  \n3) les produits  des paragraphes  a), b) 1) et b) 2) ci dessus  additionn\u00e9s  d\u2019autres  additifs.  \n \n2.- Les n\u00b0s 3003.60 et 3004.60 couvrent les m\u00e9dicaments contenant de l\u2019art\u00e9misinine (DCI) pour administration  \npar voie orale associ\u00e9e \u00e0 d\u2019autres ingr\u00e9dients pharmaceutiques actifs, ou contenant l\u2019un des principes actifs  \nsuivants, m\u00eame associ\u00e9s \u00e0 d\u2019autres i ngr\u00e9dients pharmaceutiques actifs : de l\u2019amodiaquine (DCI); de l\u2019acide  \nart\u00e9linique ou ses sels; de l\u2019art\u00e9nimol  (DCI); de l\u2019art\u00e9motil (DCI); de l\u2019art\u00e9m\u00e9ther (DCI); de l\u2019art\u00e9sunate (DCI);  \nde la chloroquine (DCI); de la dihydroart\u00e9minisinine (DCI); de la lum\u00e9 fantrine (DCI); de la m\u00e9floquine (DCI); de  \nla pip\u00e9raquine  (DCI);  de la pyrim\u00e9thamine  (DCI)  ou de  la sulfadoxine  (DCI).", "start_char_idx": 0, "end_char_idx": 2557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "200941cd-78f6-4e4a-9e32-ee17811558d0": {"__data__": {"id_": "200941cd-78f6-4e4a-9e32-ee17811558d0", "embedding": null, "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b831dd29-def8-47cb-ae7c-a20123db8836", "node_type": "4", "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "77eb3b6e39d48c9ff47f69ac8f13f9874dbb1f2356153ea4a6199b27175a9cda", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e076a90-493a-462f-a532-92b9a044b5b1", "node_type": "1", "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "e9263d0fff0709aee581d9c36d334795db272569b7d354159d1f59f963c4b03d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "606b603e-0be4-41d6-a28a-e0a3f8642be3", "node_type": "1", "metadata": {}, "hash": "ed94dedcdc8264db12b17e1046c0805e3ff42946cb58d11c4f3829d6dd523fe0", "class_name": "RelatedNodeInfo"}}, "text": "Notes  compl\u00e9mentaires  \n1/ Ne rentrent  au n\u00b0 3002.42.91.00  que les vaccins  v\u00e9t\u00e9rinaires  suivants  : \nVaccins  viraux  : \nvaccin  anti-rabique  \nvaccin  contre  la peste  \u00e9quine  \nvaccin contre la variole du dromadaire  \nvaccin  contre  les pseudopestes  aviaires  \nVaccins  bact\u00e9ridiens  : \nvaccin  contre  les ent\u00e9rotox\u00e9mies  animales  \nvaccin contre le charbon bact\u00e9ridien  \nvaccin contre le charbon symptomatique  \nvaccin  contre  les charbons  mixtes  \n2/ a- Ne rentrent  aux sous -positions  ci-apr\u00e8s  que les m\u00e9dicaments  contenant  des p\u00e9nicillines  ou des d\u00e9riv\u00e9s  de \nces produits,  \u00e0 structure  d\u2019acide  p\u00e9nicillinique,  ou des streptomycines  ou des d\u00e9riv\u00e9s  de ces produits  comme  \nsuit :", "start_char_idx": 2562, "end_char_idx": 3268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "606b603e-0be4-41d6-a28a-e0a3f8642be3": {"__data__": {"id_": "606b603e-0be4-41d6-a28a-e0a3f8642be3", "embedding": null, "metadata": {"page_label": "3", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "081e806b-0489-4f0a-824d-f759cfec0321", "node_type": "4", "metadata": {"page_label": "3", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "46940d86bfbb4a94e5837345be4cca19a6527ba3ce62687d17344fedf21ffe5d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "200941cd-78f6-4e4a-9e32-ee17811558d0", "node_type": "1", "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "54a1d4734f2b257d0de3deddcee765a6c69af8d55e63745432e90606158762a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f08385-9974-435a-aeec-d28425c18c4e", "node_type": "1", "metadata": {}, "hash": "a271ec81084d42a0a13971c94b22f5e81103a51d143668bf2727099bb661c7dc", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n3 / chap  30  \n  \n \n1) 3003.10.90.10  : \n- M\u00e9lange  st\u00e9rile  de Clavulanate  de potassium  et d\u2019amoxicilline  sodique  st\u00e9rile  \n2) 3004.10.00.40 :  \n \n \n \n \n \n \n3) 3004.10.00.50  \n- Ceftriaxone  (DCI)  \n- Streptomycine  \"\" \nb- Ne rentrent  aux n\u00b0s 3003.20.90.10  et 3004.20.00.50  que les m\u00e9dicaments  contenant  les autres  \nantibiotiques:  \n1)- pr\u00e9sent\u00e9s  sous  forme  injectable  : \n- Azithromycine  DCI \n- Ceftazidime  \"\" \n- Ciprofloxacine  \"\" \n- Levofloxacine  \"\" \n- Moxifloxacine  \"\" \n2)-pr\u00e9sent\u00e9s  sous  forme  de collyres  : \n- Acide  Fusidique  DCI \n- Azithromycine  \"\" \n- Bacitracine//  Colistine//  Hydrocortizone  \"\" \n- Ciprofloxacine  \"\" \n- Clofazimine  \n- Gentamicine  \"\" \n- Moxifloxacine  \"\" \n- Norfloxacine  \"\" \n- Ofloxacine  \"\" \n \n3)- \u00e0 base  des DCI suivantes,  sous  toute  forme  gal\u00e9nique  : \n- Anidulafungine  DCI \n- Amikacine  \"\" \n- Amphot\u00e9ricine  B \"\" \n- Aztreonam  \"\" \n- Bleomycine  \"\" \n- Caspofungine  \"\" \n- Cefditoren  Pivoxil  \"\" \n- Cefepime  \"\" \n- Cefotaxime  \"\" \n- Cefpodoxime  Proxetil  \"\" \n- Ceftaroline  fosamil  \"\" \n- Ceftazidime/Avibactam  \"\" \n- Ceftolozane/Tazbactam  \"\" \n- Cefuroxime  \"\" \n- Cefuroxime  Axetil  \"\" \n- Ertapeneme  \"\" \n- Dexamethasone  // Gentamicine  Sodium  Sulfate  \"\" \n- Dexamethasone  // Neomycine  \"\" \n- Dexamethasone  // Neomycine  // Polymyxine  B \"\" \n- Doxorubicine  (Chlorhydrate)  \"\" \n- Framycetine  (Sulfate)  // Dexamethasone  \"\" \n- Gemifloxacine  \"\" - Ampicilline/sulbactam  (sultamicilline)  (DCI)  \n- Cefot\u00e9tan  \"\" \n- Loteprednol  Etabonate  // Tobramycine  \"\" \n- Piperacilline  \"\" \n- Piperacilline  // Tazobactam  \"\" \n- Tobramycine  // Dexamethasone  \"\"", "start_char_idx": 0, "end_char_idx": 1671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f08385-9974-435a-aeec-d28425c18c4e": {"__data__": {"id_": "30f08385-9974-435a-aeec-d28425c18c4e", "embedding": null, "metadata": {"page_label": "4", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "76848cfd-028d-4b50-b0a1-7dfdf6feb893", "node_type": "4", "metadata": {"page_label": "4", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "ffffa2a43250af17457d0153e19947516f0717faaf24d26e4f8a78b828331942", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "606b603e-0be4-41d6-a28a-e0a3f8642be3", "node_type": "1", "metadata": {"page_label": "3", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "6920dc3c31a9b8d695de566f1e27f268aa378f49690b7d28d8334a04656fa0c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1d209c4-8132-4cbd-9ea6-90c8b1f8c5ed", "node_type": "1", "metadata": {}, "hash": "0cc15fb0f8c29fd6513bf259b2cfa76a1e65fd573cf1b4cac1259f2453328e0d", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n4 / chap  30  \n  \n \n- Imipeneme  // Cilastatine  \"\" \n- Levofloxacine  Hemihydratee  \"\" \n- Linezolide  DCI \n- Lymecycline  \"\" \n- Meropeneme  \"\" \n- Mupirocine  \"\" \n- Neomycine  // Polymyxine  B // Nystatine  \"\" \n- Rifampicine/Isoniazide  \"\" \n- Rifampicine/Isoniazide  /Pyrazinamide  \"\" \n- Sufadiazine  Argentique  \"\" \n- Sufadiazine  \"\" \n- Teicoplanine  \"\" \n- Tetracycline  / Metronidazole  // Sous  Citrate  de Bismuth Potassique  \"\" \n- Tigecycline  \"\" \n- Vancomycine  \"\" \n2/bis. - Ne rentrent  au n\u00b0 3004.20.00.60  que les m\u00e9dicaments  contenant  les autres  antibiotiques:  \n- Rifampicine  \"\" \n- Rifampicine/Isoniazide  /Pyrazinamide/Ethambutol  \"\" \n- Josamycine  \"\" \n2/ter. - Ne rentrent  au n\u00b0 3004.20.00.65  que les m\u00e9dicaments  contenant  les autres  antibiotiques:  \n- Clarithromycine  \"\" \n- Cefixime  \"\" \n- Cefixime  Trihydrate  \"\" \n3/ Ne rentrent  aux n\u00b0s 3003.31.00.10,  3003.39.80.10,  3004.31.00.30,  3004.32.00.60,  3004.39.00.70  que les \nm\u00e9dicaments  contenant  des hormones  ou d\u2019autres  produits du  n\u00b0 29.37  suivants:  \na- Contenant  de l\u2019insuline  \n- Insuline  Aspart  DCI \n- Insuline  Degludec  \"\" \n- Insuline  Degludec  // Asprate  \"\" \n- Insuline  Detemir  \"\" \n- Insuline  Glargine  \"\" \n- Insuline  Glulisine  \"\" \n- Insuline  Lispro  \"\" \nb-Contenant  des hormones  corticost\u00e9ro\u00efdes,  leurs  d\u00e9riv\u00e9s  ou analogues  structurels  \n1\u00b0) pr\u00e9sent\u00e9s  sous  forme  injectable  : \nBetamethasone  DCI \nMethylprednisolone  \"\" \n2\u00b0) pr\u00e9sent\u00e9s  sous  forme  de collyres  : \nDexamethasone  DCI \nPrednisolone  \"\" \n3\u00b0) \u00e0 base  des DCI suivantes,  sous  toute  forme  gal\u00e9nique  : \n- Beclomethasone  DCI \n- Bud\u00e9sonide  \"\" \n- Clob\u00e9tasol  \"\" \n- Estradiol  \"\" \n- Estradiol  // Dydrogesterone  \"\" \n- Estradiol  // Norethisterone  \"\" \n- Estriol  \"\" \n- Fluticasone  \"\" \n- Fluticasone  /Salmeterol  \"\" \n- Fluticasone  Furoate  \"\" \n- Furoate  de Fluticasone  /Vilanterol  \"\" \n- Fluticasone  Propionate  /Salmeterol  \"\"", "start_char_idx": 0, "end_char_idx": 1960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1d209c4-8132-4cbd-9ea6-90c8b1f8c5ed": {"__data__": {"id_": "c1d209c4-8132-4cbd-9ea6-90c8b1f8c5ed", "embedding": null, "metadata": {"page_label": "5", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "a62a1bc9-e80e-4dd8-9f88-2d7d4bff63a5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "be003612ee6a87aec5f693df6554c8379978df2b7ea252a497a9dd7a3ac90da8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f08385-9974-435a-aeec-d28425c18c4e", "node_type": "1", "metadata": {"page_label": "4", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "49439618a63ac6556cfe361ebfa83f9c6e9a1f529c31cb4c9a9409653d938f24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c989c2c9-e961-45a3-b871-14cf0e2906c4", "node_type": "1", "metadata": {}, "hash": "589f14522390506d3ace9f71378db105b627758c129d3f11e58a2aa85a268e43", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n5 / chap  30  \n  \n \n- Fluticasone  Propionate  /Salmeterol  Xinafoate  \"\" \n- Hydroxyprogesterone  Caproate  \"\" \n- Lactobacillus  Acidophilus  // Estriol  \"\" \n- Medrogestone  \"\" \n- Progesterone  \"\" \n- Promestriene  \"\" \n- Testosterone  (Enanthate)  \"\" \nc- Contenant  autres  hormones  ou autres  produits  du n\u00b0 29.37  \n- Calcitonine  DCI \n- Dinoprostone  \"\" \n- Follitropine  Alfa \"\" \n- Follitropine  alfa // Lutropine  Alfa \"\" \n- Ganirelix  \"\" \n- levothyroxine  \"\" \n- Misoprostol  \"\" \n- Menotropine  \"\" \n- Noradrenaline  \"\" \n- Oxytocine  \"\" \n- Prostaglandine  \"\" \n- Somatropine  \"\" \n3/bis. - Ne rentrent  aux n\u00b0s 3004.31.00.40  et  3004.32.00.70  et  3004.39.00.75  que  les  m\u00e9dicaments  \ncontenant  des hormones  ou d\u2019autres  produits  du n\u00b0 29.37  suivants:  \na)- Contenant  de l\u2019insuline  \n- Insuline  Humaine  Biogenetique  DCI \nb)-Contenant  des hormones  corticost\u00e9ro\u00efdes,  leurs  d\u00e9riv\u00e9s  ou analogues  structurels  \n- Desogestrel  \nc)- Contenant  autres  hormones  ou autres  produits  du n\u00b0 29.37  \n- Acetate  d'abirat\u00e9rone  DCI \n3/ter. - Ne rentrent  aux n\u00b0s 3004.32.00.80  et 3004.39.00.80  que les m\u00e9dicaments  contenant  des hormones  ou \nd\u2019autres  produits  du n\u00b0 29.37  suivants:  \na)-Contenant  des hormones  corticost\u00e9ro\u00efdes,  leurs  d\u00e9riv\u00e9s  ou analogues  structurels  \nBetamethasone  DCI \nLevonorgestrel  // Ethinylestradiol  \"\" \nPrednisone  \"\" \nb)- Contenant  autres  hormones  ou autres  produits  du n\u00b0 29.37  \nDesogestrel  // Ethinylestradiol  DCI \n4/ Ne rentrent  aux n\u00b0s 3003.49.90.10  et 3004.49.00.35  que les m\u00e9dicaments  contenant  des alcalo\u00efdes  ou leurs  \nd\u00e9riv\u00e9s  suivantes  : \n- Alverine  // Simethicone  DCI \n- Articaine  // Adrenaline  \"\" \n- Atenolol  // Chlortalidone  \"\" \n- Charbon  Active  // Papaverine  (Chlorhydrate  ) \"\" \n- Chlorhydrate  Articaine  // Adrenaline  \"\" \n- Chlorydrate  de Mepivacaine  \"\" \n- Digoxine  \"\" \n- Lidocaine  // Benzalkonium  Chlorure  \"\" \n- Lidocaine  // Prilocaine  \"\" \n- Lidocaine  de base  // Cetrimide  \"\" \n- Oxetacaine  // Magnesium  Oxyde  Leger  // Aluminium  Oxyde  \"\" \n- Oxybuprocaine  \"\" \n- Vincristine  (Sulfate)  (DCI)  \"\"", "start_char_idx": 0, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c989c2c9-e961-45a3-b871-14cf0e2906c4": {"__data__": {"id_": "c989c2c9-e961-45a3-b871-14cf0e2906c4", "embedding": null, "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "306caaa3-2674-4c00-a625-ee0abca82678", "node_type": "4", "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "15f69bc7f24cc428e0521a08a01a7b0b577c388f46323e5b5619a8179dffd1e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1d209c4-8132-4cbd-9ea6-90c8b1f8c5ed", "node_type": "1", "metadata": {"page_label": "5", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "7b0700f4928914a7fe08d5d7b342f56e0011b5fd87ad9a2af8e73c3f6e3e42ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "059a7f70-4a8a-4d82-ac8d-e6abad27510a", "node_type": "1", "metadata": {}, "hash": "3efb183b92072af8fa57ea3541f0aeda68baaa1d23f1c7c60b98bb1b6adde180", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n6 / chap  30  \n  \n \n4/bis. - Ne rentrent  au n\u00b0 3004.41.00.30  que les m\u00e9dicaments  contenant  des alcalo\u00efdes  ou leurs  d\u00e9riv\u00e9s  \nsuivants  : \n- Ephedrine  (Chlorhydrate)  DCI \n4/ter. - Ne rentrent  au n\u00b0 3004.49.00.45  que les m\u00e9dicaments  contenant  des alcalo\u00efdes  ou leurs  d\u00e9riv\u00e9s  \nsuivants  : \n- Atropine  DCI \n- Theophylline  \"\" \n \n5/ Ne rentrent  aux n\u00b0s 3003.90.95.00,  3004.50.00.81  et 3004.90.00.70  que les m\u00e9dicaments  contenant  : \na)- des principes  actifs  contre  le paludisme  suivants  : \n- Atovaquone  // Proguanil  (chlorhydrate)  DCI \nb)- les DCI suivantes : \n1- pr\u00e9sent\u00e9s  sous  forme  injectable  : \n \n- Acetylsalicylate  De Lysine  DCI \n- Aciclovir  \"\" \n- Acide  Tranexamique  \"\" \n- Amiodarone  (Chlorhydrate)  \"\" \n- Chlorpromazine  \"\" \n- Dobutamine  (Chlorhydrate)  \"\" \n- Drotaverine  \"\" \n- Esomeprazole  \"\" \n- Etamsylate  \"\" \n- Fluconazole  \"\" \n- Levomepromazine  (Maleate)  \"\" \n- Meloxicam  \"\" \n- Nimodipine  \"\" \n- Omeprazole  \"\" \n- Paracetamol  \"\" \n- Phloroglucinol  // Trimethylphloroglucinol  \"\" \n- Salbutamol  Sulfate  \"\" \n- Bupivacaine  \"\" \n2- pr\u00e9sent\u00e9s  sous  forme  de collyres :  \n- Chlorure  de Sodium  DCI \n- Diclofenac  Sodique  \"\" \n- Hexamidine  (Di-Isethionate)  \"\" \n- Indometacine  \"\" \n- Ketotifene  \"\" \n3- \u00e0 base  des DCI suivantes,  sous  toutes  formes  gal\u00e9niques  : \n- Abacavir  (DCI)  \n- Abacavir/Lamivudine  (DCI)  \n- Acetylleucine  (DCI)  \n- Acide Alendronique //  \nCholecalciferol (DCI)  \n- Acide  Amin\u00e9s+  \u00c9lectrolytes  : \nAlanine, Arginine, Acide Aspartique,  \nAcide  Glutamique,  Glycine,  Histidine,  \nIsoleucine, Leucine, Ac\u00e9tate De  \nLysine (\u00c9quivalent \u00c0 Lysine),  \nM\u00e9thionine, Ph\u00e9nylalanine, Proline,  \nS\u00e9rine,  Th\u00e9ronine, Tryptophane,  Tyrosine,  Valine,  Ac\u00e9tate  De Sodium  \nTrihydrat\u00e9, Chlorure De  Potassium,  \nChlorure  De Magn\u00e9sium  \nHexahydrat\u00e9, Glyc\u00e9rophosphate De  \nSodium Hydrat\u00e9.", "start_char_idx": 0, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "059a7f70-4a8a-4d82-ac8d-e6abad27510a": {"__data__": {"id_": "059a7f70-4a8a-4d82-ac8d-e6abad27510a", "embedding": null, "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "306caaa3-2674-4c00-a625-ee0abca82678", "node_type": "4", "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "15f69bc7f24cc428e0521a08a01a7b0b577c388f46323e5b5619a8179dffd1e3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c989c2c9-e961-45a3-b871-14cf0e2906c4", "node_type": "1", "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "c5d1e1f40a789bf411357dca3d8c1e349861ea2fb250bbe327950e44cc207947", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c5d0ff4-6a3b-4039-99d5-f188e6fa1281", "node_type": "1", "metadata": {}, "hash": "ae2773d02d10f0ac469117472a75c8338bacc9851746d93a605435aef8a200c8", "class_name": "RelatedNodeInfo"}}, "text": "// Solution De  \nGlucose + Caclium : Glucose  \nMonohydrat\u00e9 (\u00c9quivalent Au  \nGlucose Anhydre), Chlorure De  \nCalcium  Dihydrat\u00e9  (DCI)  \n- Acide  ac\u00e9tylsalicylique  (DCI)  \n- Acide  Gadoterique  (DCI)  \n- Acide  Ibandronique  Equivalent  A \nIbandronate  De Sodium  Monohydrate  (DCI)  \n- Acide N -Acetyl Aspartyl Glutamique  \nSodique  (DCI)  \n- Acide  Zoledronique  (DCI)  \n- Adapalene  (DCI)  \n- Adapalene // Peroxyde De  \nBenzoyle  (DCI)  \n- Aflibercept  (DCI)  \n-Agalsidase  beta  (DCI)  \n- Agomelatine  (DCI)  \n- Alcool  Dichlorobenzylique  //", "start_char_idx": 1902, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c5d0ff4-6a3b-4039-99d5-f188e6fa1281": {"__data__": {"id_": "5c5d0ff4-6a3b-4039-99d5-f188e6fa1281", "embedding": null, "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c695a13-8013-42b2-ac4d-90a6443e5881", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "774eaa5a845d3891e7d31a62636fcc145544e71d7715d81156dff7b4e3e009c4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "059a7f70-4a8a-4d82-ac8d-e6abad27510a", "node_type": "1", "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "e64162913cfb815077056743621e1f88b2c7c775c4dad3e4ec8345eae258b68f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe1b3b08-1b5d-49b2-ba35-f8b9e30406d7", "node_type": "1", "metadata": {}, "hash": "e8f04dc31bd85eccd2ccec23a5af42bae83f5ed5328a13a0e215291398ce8409", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n7 / chap 30   \n Amylmetacresol  (DCI)  \n- Alfuzocine  (DCI)  \n- Alfuzosine  (Chlorhydrate)  (DCI)  \n- Ambenonium  (Chlorure)  (DCI)  \n- Amidotrizoate De Meglumine //  \nAmidotrizoate  De Sodium  (DCI)  \n- Amlodipine  // Atrovastatine  (DCI)  \n- Amlodipine  // Hydrochlorothiazide  \n// Valsartan  (DCI)  \n- Amlodipine  // Perindopril  (DCI)  \n- Amlodipine  // Valsartan  (DCI)  \n- Amorolfine  (DCI)  \n- Apixaban  (DCI)  \n- Aprepitant  (DCI)  \n- Art\u00e9sunate  (DCI)  \n- Atomox\u00e9tine(DCI)  \n- Azathiopurine  (DCI)  \n- Azelastine  (DCI)  \n- Baclofene  (DCI)  \n- Beclomethasone  // Formoterol  \nFumarate Dihydrate  (DCI)  \n- B\u00e9daquiline(DCI)  \n- Bemiparine  (DCI)  \n- B\u00e9sifloxacine  chlorhydrate  (DCI)  \n- Beta  Sitosterol  (DCI)  \n- Betamethasone  (Dipropionate)  // \nBethamethasone Phosphate  \nDisodique  (DCI)  \n- Betaxolol  (DCI)  \n- Biclothymol  (DCI)  \n- Bimatoprost  (DCI)  \n- Bimatoprost  // Timolol  (DCI)  \n- Bisoprolol  (Hemifumarate)  (DCI)  \n- Bisoprolol  (Hemifumarate)  // \nHydrochlorothiazide  (DCI)  \n- Bicalutamide  (DCI)  \n- Bisoprolol  // Amlodipine  (DCI)  \n- Bortezomib  (DCI)  \n- Bosentan  (DCI)  \n- Brimonidine  (Tartrate)  (DCI)  \n- Brimonidine  (Tartrate)  // Timolol  \nMaleate  (DCI)  \n- Brinzolamide  (DCI)  \n- Brinzolamide  // Timolol  (Maleate)  \n(DCI)  - Bromure  De Glycopyrronium  (DCI)  \n- Budesonide  // Formoterol  \nFumarate  Dihydrate  (DCI)  \n- Budesonide  // Salmeterol  (DCI)  \n- Bupropion  (Chlorhydrate)  (DCI)  \n- Cabergoline  (DCI)  \n- Calcipotriol  // Betamethasone  (DCI)  \n- Calcium  (Glucoheptonate)  // \nCalcium (Gluconate)  (DCI)  \n- Calcium  / Fer (DCI)  \n- Candesartan  Cilexetil  (DCI)  \n- Candesartan Cilexetil //  \nHydrochlorothiazide  (DCI)  \n- Capecitabine  (DCI)  \n- Carbamaz\u00e9pine  (DCI)  \n- Carbomere  974P  (DCI)  \n- Carbomere  980 (DCI)  \n- Carboplatine  (DCI)  \n- Carfilzomib  (DCI)  \n- Carmellose  (Sodique)  (DCI)  \n- Carteolol  (Chlorhydrate)  (DCI)  \n- Carvedilol  // Ivabradine  (DCI)  \n- Cetrorelix  (DCI)  \n- Charbon  Active  // Dimeticone  (DCI)  \n- Charbon", "start_char_idx": 0, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe1b3b08-1b5d-49b2-ba35-f8b9e30406d7": {"__data__": {"id_": "fe1b3b08-1b5d-49b2-ba35-f8b9e30406d7", "embedding": null, "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c695a13-8013-42b2-ac4d-90a6443e5881", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "774eaa5a845d3891e7d31a62636fcc145544e71d7715d81156dff7b4e3e009c4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c5d0ff4-6a3b-4039-99d5-f188e6fa1281", "node_type": "1", "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "73e91c525e33bc77ede2007c995d56a63c105cf9b1a64137c44947e6eef4c2cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f9530ce-d89f-4c87-9d47-d1a26969abf6", "node_type": "1", "metadata": {}, "hash": "18e8a96fc2f9ce68471e3b1210e76c173373693df083d65a0c3fe4ca61c888d3", "class_name": "RelatedNodeInfo"}}, "text": "(DCI)  \n- Candesartan Cilexetil //  \nHydrochlorothiazide  (DCI)  \n- Capecitabine  (DCI)  \n- Carbamaz\u00e9pine  (DCI)  \n- Carbomere  974P  (DCI)  \n- Carbomere  980 (DCI)  \n- Carboplatine  (DCI)  \n- Carfilzomib  (DCI)  \n- Carmellose  (Sodique)  (DCI)  \n- Carteolol  (Chlorhydrate)  (DCI)  \n- Carvedilol  // Ivabradine  (DCI)  \n- Cetrorelix  (DCI)  \n- Charbon  Active  // Dimeticone  (DCI)  \n- Charbon Vegetal // Extrait De  \nRhubarbe  // Feuilles  De Sene  // \nSoufre  (DCI)  \n- Chlorhydrate  De Bendamustine  \n(DCI)  \n- Chlorhydrate  De Cyclopentolate  (DCI)  \n- Chlormadinone  (Acetate)  // \nEthinylestradiol  (DCI)  \n- Chlormadione  Acetate  // Ethinyl  \nEstradiol Micronise  (DCI)  \n- Chlorure  De Sodium  // Chlorure  De \nPotassium // Chlorure De Calcium  \nDihydrate // Chlorure De  \nMagnesium Hexahydrate // Acetate  \nDe Sodium  // Acide  L-Malique  (DCI)  \n- Chlorure De Sodium // Lactate De  \nSodium // Chlorure De Calcium //  \nChlorure  De Magnesium  \nHexahydrate  // Glucose  Monohydrat  \n(DCI)  \n- Choriogonadotropine  Alfa (DCI)  \n- Ciclosporine  (DCI)  \n- Cinacalcet  (DCI)  - Cisatracurium  (Besilate)  (DCI)  \n- Cisplatine  (DCI)  \n- Clonazepam  (DCI)  \n- Clostridium  Botulinum  Type  A (DCI)  \n- Clozapine  (DCI)  \n- Complexe D'Hydroxide Ferrique  \nSaccharose  (DCI)  \n- Complexe D'Hydroxyde Ferrique  \nSaccharose  (DCI)  \n- Complexe  Fer-Sucrose  (DCI)  \n- Cromoglicate  De Sodium  (DCI)  \n- Cyclophosphamide  (DCI)  \n- Cyclos\u00e9rine  (DCI)  \n- Cyproterone  (Acetate)  (DCI)  \n- Cytarabine  (DCI)  \n- Dabigatran  (DCI)  \n- Dabigatran Etexilate (Mesilate)  \n(DCI)  \n- Dapsone/oxalate  de fer (DCI)  \n- Darbepoeitin  Alfa (DCI)  \n- Darunavir  (DCI)  \n- Daunorubicine  Hydrochloride  (DCI)  \n- Deferasirox  (DCI)  \n- Deferiprone  (DCI)  \n- Deferoxamine Methane (Sulfonate)  \n(DCI)  \n- Deflazacorte  (DCI)  \n- Delamanid  (DCI)  \n- Delapril  // Indapamide  (DCI)  \n- Dequalinium  (Chlorhydrate)  (DCI)  \n- Desmopressine  (DCI)  \n- Dexm\u00e9d\u00e9tomidine  (DCI)  \n- Dexpanthenol  (DCI)  \n- Dexpanthenol // Alcool  \nPolyvinylique  (DCI)  \n- Diacerheine  (DCI)  \n- Dianeal  (DCI)  \n- Dienogest  (DCI)  \n- Dienogest // Valertae D'Estradiol  \n(DCI)  \n- Diosmectite  (DCI)  \n-", "start_char_idx": 1674, "end_char_idx": 3842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f9530ce-d89f-4c87-9d47-d1a26969abf6": {"__data__": {"id_": "1f9530ce-d89f-4c87-9d47-d1a26969abf6", "embedding": null, "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "4c695a13-8013-42b2-ac4d-90a6443e5881", "node_type": "4", "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "774eaa5a845d3891e7d31a62636fcc145544e71d7715d81156dff7b4e3e009c4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe1b3b08-1b5d-49b2-ba35-f8b9e30406d7", "node_type": "1", "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "56e9666ad2b3a05c163c47b78645f0f45b634d687cac9648468be34f8acad645", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ecb6cb2-e7dd-4680-9233-fc83d5b5da8b", "node_type": "1", "metadata": {}, "hash": "e041bda7e7556d76256eec082268720a4e0654b14dd370113fde477c8898e21d", "class_name": "RelatedNodeInfo"}}, "text": "Methane (Sulfonate)  \n(DCI)  \n- Deflazacorte  (DCI)  \n- Delamanid  (DCI)  \n- Delapril  // Indapamide  (DCI)  \n- Dequalinium  (Chlorhydrate)  (DCI)  \n- Desmopressine  (DCI)  \n- Dexm\u00e9d\u00e9tomidine  (DCI)  \n- Dexpanthenol  (DCI)  \n- Dexpanthenol // Alcool  \nPolyvinylique  (DCI)  \n- Diacerheine  (DCI)  \n- Dianeal  (DCI)  \n- Dienogest  (DCI)  \n- Dienogest // Valertae D'Estradiol  \n(DCI)  \n- Diosmectite  (DCI)  \n- Dipropionate De Beclomethasone  \nAnhydre  // Fumarate  De Formoterol  \nDihydrate  (DCI)  \n- Docetaxel  (DCI)", "start_char_idx": 3434, "end_char_idx": 3951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ecb6cb2-e7dd-4680-9233-fc83d5b5da8b": {"__data__": {"id_": "1ecb6cb2-e7dd-4680-9233-fc83d5b5da8b", "embedding": null, "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "13682a38-9c55-46cf-b46c-68a644d4a2fc", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "878a9892e3ab18bee12bd271badbb1fb8473e3c6a1b7438bd129bb5faaed9bd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f9530ce-d89f-4c87-9d47-d1a26969abf6", "node_type": "1", "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "534912f537f804102b7fd4f6c6902b9809a3ee0563d565539e801cfe477721c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd9cedc5-6eec-4e8d-a91f-48eae517fee7", "node_type": "1", "metadata": {}, "hash": "85321762cfc9897ac9add72b8a31bf434d92f450c74f33478c1cf32b4ca010c8", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n8 / chap 30   \n - Dolut\u00e9gravir  (DCI)  \n- Dolutegravir/Emtricitabine/  \nTenofovir  (alafenamide)  (DCI)  \n- Dolutegravir/Lamivudine/  \nTenofovir  (disoproxil  fumarate)  (DCI)  \n- Donepezil  (Chlorhydrate)  (DCI)  \n- Dorzolamide  (DCI)  \n- Dorzolamide  (Chlorhydrate)  (DCI)  \n- Dorzolamide  (Chlorhydrate)  // \nTimolol  (Maleate)  (DCI)  \n- Dorzolamide  // Timolol  (DCI)  \n- Drospirenone  // Ethinylestradiol  \n(DCI)  \n- Duloxetine  (Chlorhydrate)  (DCI)  \n- Dutasteride  (DCI)  \n- Efavirenz  (DCI)  \n- Efavirenz //  emtricitabine  // \nT\u00e9nofovir  (disoproxil  maleate)  (DCI)  \n- Efavirenz // emtricitabine //  \nT\u00e9nofovir  (disoproxil  Fumarate)  \n(DCI)  \n- Eletriptan  (DCI)  \n- Eltrombopaq  Olamine  (DCI)  \n- Entacapone  // Levodopa  // \nCarbidopa  (DCI)  \n- Entecavir  (DCI)  \n- Enzalutamide  (DCI)  \n- Epirubicine  (Chlorhydrate)  (DCI)  \n- Epoetine  Alfa (DCI)  \n- Epoetine  Beta  (DCI)  \n- Eptacog  Alpha  Activ (R  F Vii) (DCI)  \n- Eribyline  Mesilate  (DCI)  \n- Erythropoetine  (DCI)  \n- Ethinylestradiol  Dienogest  (DCI)  \n- Etomidate  (DCI)  \n- Etonogestrel  (DCI)  \n- Etoposide  (DCI)  \n- Exemestane  (DCI)  \n- Ezetimib  (DCI)  \n- Facteur  Ix De Coagulation  Humaine  \n(DCI)  \n- Facteur  Viii De Coagulation  (DCI)  \n- Fampridine  (DCI)  \n- Febuxostat  (DCI)  \n- Fenofibrate  (DCI)  - Fentanyl  (DCI)  \n- Fer (DCI)  \n- Flucytosine  (DCI)  \n- Fludarabine  (Phosphate)  (DCI)  \n- Fluoresceine  (Sodique)  (DCI)  \n- Fluorometholone  (DCI)  \n- Fluorouracil  (DCI)  \n- Fluvoxamine  (Maleate)  (DCI)  \n- Folinate  (De Calcium)  (DCI)  \n- Fondaparinux  (Sodique)  (DCI)  \n- Formoterol  (Fumarate)  (DCI)  \n- Fraction  Phospholipidique  De \nPoumon (DCI)  \n- Fulvestrant  (DCI)  \n- Fumarate  De Formoterol  Dihydrate  \n// Budesonide  (DCI)  \n- Gabapentine  (DCI)  \n- Gadobutrol  (DCI)  \n- Ganciclovir  (DCI)  \n- Gefitinib  (DCI)  \n- Gelatine  Fluide  Modifiee  (DCI)  \n- Gemcitabine  (DCI)  \n- Gemcitabine  Chlorhydrate  (DCI)  \n- Glucagon  Biogenetique  (DCI)  \n- Glucosamine  (DCI)  \n- Glucosamine", "start_char_idx": 0, "end_char_idx": 2054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd9cedc5-6eec-4e8d-a91f-48eae517fee7": {"__data__": {"id_": "dd9cedc5-6eec-4e8d-a91f-48eae517fee7", "embedding": null, "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "13682a38-9c55-46cf-b46c-68a644d4a2fc", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "878a9892e3ab18bee12bd271badbb1fb8473e3c6a1b7438bd129bb5faaed9bd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ecb6cb2-e7dd-4680-9233-fc83d5b5da8b", "node_type": "1", "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "8b5da27955a5118e4268c178a860cf67e7cf90da11acd248c649e6bc5f8e58cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb4d472-fc1a-450d-b588-eda53e5f3f02", "node_type": "1", "metadata": {}, "hash": "7d37b1c6c7fe767346bbdcfbb18001a8ec0113952dab3497cc3506b4e4bb85d1", "class_name": "RelatedNodeInfo"}}, "text": "(Fumarate)  (DCI)  \n- Fraction  Phospholipidique  De \nPoumon (DCI)  \n- Fulvestrant  (DCI)  \n- Fumarate  De Formoterol  Dihydrate  \n// Budesonide  (DCI)  \n- Gabapentine  (DCI)  \n- Gadobutrol  (DCI)  \n- Ganciclovir  (DCI)  \n- Gefitinib  (DCI)  \n- Gelatine  Fluide  Modifiee  (DCI)  \n- Gemcitabine  (DCI)  \n- Gemcitabine  Chlorhydrate  (DCI)  \n- Glucagon  Biogenetique  (DCI)  \n- Glucosamine  (DCI)  \n- Glucosamine  (Sulfate)  (DCI)  \n- Gosereline  (Acetate)  (DCI)  \n- Heparine  Sodique  (DCI)  \n- Homeo  (DCI)  \n- Hyaluronate  (Sodium)  (DCI)  \n- Hydrocortisone  \n(Hydrogenosuccinate)  (DCI)  \n- Hydroxycarbamide  (DCI)  \n- Hydroxyde  Ferrique  Saccharose  \n(DCI)  \n- Hydroxyethylamidon  130 000 // \nChlorure De  Sodium  (DCI)  \n- Hypromellose  (DCI)  \n- Ibrutinib  (DCI)  \n- Ifosfamide  (DCI)  \n- Imatinib  (DCI)  \n- Imigulcerase  (DCI)  \n- Indacaterol  Maleate  (DCI)  \n- Indacaterol  Maleate  // Bromure  De Glycopyrronium  (DCI)  \n- Indapamide  // Amlodipine  (DCI)  \n- Insaponifiable D'Huile D'Avocat - \nSoja  (DCI)  \n- Interferon  Beta -1A (DCI)  \n- Interferon  Beta -1B (DCI)  \n- Iodixanol  (DCI)  \n- Iohexol  (DCI)  \n- Iopromide  (DCI)  \n- Ipratropium  (Bromure)  (DCI)  \n- Ipratropium  // Fenoterol  (DCI)  \n- Irbesartan  // Amlodipine  (DCI)  \n- Irinotecan Trhydrate Chlorhydrate  \n(DCI)  \n- Isoflurane  (DCI)  \n- Isoniazide  (DCI)  \n- Ivabradine  (Chlorhydrate)  (DCI)  \n- k\u00e9tamine  hydrochlorid  (DCI)  \n- Ketoconazole  (DCI)  \n- Ketorolac  // Tromethamine  (DCI)  \n- Ketotifene  Fumarate  (DCI)  \n- Lamivudine  (DCI)  \n- Lamivudine/Zidovudine  (DCI)  \n- Lamotrigine  (DCI)  \n- Lanreotide  (DCI)  \n- Laronidase  (DCI)  \n- Latanoprost  (DCI)  \n- Latanoprost  // Timolol  (DCI)  \n- Ledipasvir  // Sofosbuvir  (DCI)  \n- Leflunomide  (DCI)  \n- Lenograstim  (DCI)  \n- Levetiracetam  (DCI)  \n- Levocabastine  (Chlorhydrate)  (DCI)  \n- Levodopa  // Benzerazide  (DCI)  \n- Levonorgestrel  (DCI)  \n- Lisinopril  Dihydrate  // Amilodipine  \n(DCI)  \n- Loteprednol  Etabonate  (DCI)  \n- Lopinavir/Ritonavir  (DCI)  \n- Lutropine  Alfa (DCI)  \n-", "start_char_idx": 1643, "end_char_idx": 3685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb4d472-fc1a-450d-b588-eda53e5f3f02": {"__data__": {"id_": "1bb4d472-fc1a-450d-b588-eda53e5f3f02", "embedding": null, "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "13682a38-9c55-46cf-b46c-68a644d4a2fc", "node_type": "4", "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "878a9892e3ab18bee12bd271badbb1fb8473e3c6a1b7438bd129bb5faaed9bd8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd9cedc5-6eec-4e8d-a91f-48eae517fee7", "node_type": "1", "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "45ff9799ba38014b01b063a95d2b9bf8a22db651125597934092e772cd6340a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acecd13e-28ee-49a8-862d-cd7cfb6a2972", "node_type": "1", "metadata": {}, "hash": "156a3f20011f65a86bb622561cb231966ce14b35a354076bc69d4ec1db638f8a", "class_name": "RelatedNodeInfo"}}, "text": "- Latanoprost  // Timolol  (DCI)  \n- Ledipasvir  // Sofosbuvir  (DCI)  \n- Leflunomide  (DCI)  \n- Lenograstim  (DCI)  \n- Levetiracetam  (DCI)  \n- Levocabastine  (Chlorhydrate)  (DCI)  \n- Levodopa  // Benzerazide  (DCI)  \n- Levonorgestrel  (DCI)  \n- Lisinopril  Dihydrate  // Amilodipine  \n(DCI)  \n- Loteprednol  Etabonate  (DCI)  \n- Lopinavir/Ritonavir  (DCI)  \n- Lutropine  Alfa (DCI)  \n- Macrogol  4000  (DCI)  \n- Magnesium  (Sulfate)  (DCI)  \n- Manidipine  Chlorhydrate  (DCI)", "start_char_idx": 3297, "end_char_idx": 3775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acecd13e-28ee-49a8-862d-cd7cfb6a2972": {"__data__": {"id_": "acecd13e-28ee-49a8-862d-cd7cfb6a2972", "embedding": null, "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b3aefd5a-5a60-4bab-8962-da668c9f9fc5", "node_type": "4", "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "025d683219d63191006983cfecf66d4a566bc251e035758389d9de7412ab169a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb4d472-fc1a-450d-b588-eda53e5f3f02", "node_type": "1", "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "581344a0a4368ac86ff786e9751e6c9388bfda8baf32379966b4635237799026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f9a1918-fd27-494e-934f-82762c6719e6", "node_type": "1", "metadata": {}, "hash": "06b707f6c9388d57915910c8dd1733d77881c906adc2f3d01541878f3c12ef49", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n9 / chap 30   \n - Melphalan  (DCI)  \n- Memantine  (DCI)  \n- Memantine  Hydrochlorhdrate  (DCI)  \n- Mercaptopurine  (DCI)  \n- Mesalazine  (DCI)  \n- Mesna  (DCI)  \n- Methotrexate  (DCI)  \n- Methylthionimium  Hydroxyde  // \nNaphazoline Nitrate  (DCI)  \n- Metoprolol  (DCI)  \n- Miconazole  (DCI)  \n- Midazolam  (DCI)  \n- Milrinone  (DCI)  \n- Mofetil  Mycophenolate  (DCI)  \n- Molnupiravir  (DCI)  \n- Molsidomine  (DCI)  \n- Mometasone  (Furoate)  (DCI)  \n- Montelukast  (DCI)  \n- Montelukast  Sodique  (DCI)  \n- Mycophenolate  Mofetil  (DCI)  \n- Nadroparine  Calcique  (DCI)  \n- Nebivolol  (DCI)  \n- Nefopam  (DCI)  \n- Neostigmine  (Methylsulfate)  (DCI)  \n- N\u00e9virapine(DCI)  \n- Nicardipine  (Chlorhydrate)  (DCI)  \n- Nicorandil  (DCI)  \n- Nifedipine  // Atenolol  (DCI)  \n- Nilotinib  (DCI)  \n--Nirmatrelvir  / Ritonavir  (DCI)  \n- Nonacog Alfa (Facteur Ix De  \nCoagulation  Recombinant)  (DCI)  \n- Nutrineal  (DCI)  \n- Octocog  Alpha  (DCI)  \n- Octreotide  (DCI)  \n- Olmesartan  Medoxomil  (DCI)  \n- Olopatadine  (DCI)  \n- Ondansetron  (DCI)  \n- Ondansetron  (Chlohydrate)  (DCI)  \n- Orlistat  (DCI)  \n- Otilonium  Bromure  (DCI)  \n- Oxaliplatine  (DCI)  - Oxcarbazepine  (DCI)  \n- Oxyde  D'Aluminium  // Hydroxyde  \nDe Magnesium  (DCI)  \n- Paclitaxel  (DCI)  \n- Palbociclib  (DCI)  \n- Par\u00e9coxib  sodium  (DCI)  \n- Paricalcitol  (DCI)  \n- Pemetrexed  Disodique  (DCI)  \n- Pemetrexed  Disodique  \n(Heptahydrate)  (DCI)  \n- Perindopril (Arginine) //  \nAmlodipine  (Besilate)  (DCI)  \n- Perindopril  Arginine  // Fumarate  \nDe Bisoprolol  (DCI)  \n- Perindopril  Arginine  // Indapamide  \n// Amlodipine  (DCI)  \n- Peroxyde  De Benzoyle  (DCI)  \n- Ph\u00e9nobarbital  (DCI)  \n- Phenylephrine  (DCI)  \n- Pipotiazine  (DCI)  \n- Polystyrene  Sulfonate  De Calcium  \n(DCI)  \n- Polystyrene  Sulfonate  De Sodium  \n(DCI)  \n- Pramipexole  (DCI)  \n- Pravastatine  // Fenofibrate  (DCI)  \n- Propericiazine  (DCI)  \n- Propofol  (DCI)  \n- Protamine  (Sulfate)  (DCI)  \n- Prothionamide  (DCI)  \n- Pyridostigmine  (Bromure)", "start_char_idx": 0, "end_char_idx": 2046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f9a1918-fd27-494e-934f-82762c6719e6": {"__data__": {"id_": "1f9a1918-fd27-494e-934f-82762c6719e6", "embedding": null, "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "b3aefd5a-5a60-4bab-8962-da668c9f9fc5", "node_type": "4", "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "025d683219d63191006983cfecf66d4a566bc251e035758389d9de7412ab169a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acecd13e-28ee-49a8-862d-cd7cfb6a2972", "node_type": "1", "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "90fc1b86f7ec672657f97da961098f8c63ceeed511c32abe307f79ef1509659c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a735ae87-5856-4bac-8a41-9328a34d6600", "node_type": "1", "metadata": {}, "hash": "b1e26e34c4700d62afc2b0c418e0e73c10412b3f4ee7e5c60946c7abc112825f", "class_name": "RelatedNodeInfo"}}, "text": "Amlodipine  (DCI)  \n- Peroxyde  De Benzoyle  (DCI)  \n- Ph\u00e9nobarbital  (DCI)  \n- Phenylephrine  (DCI)  \n- Pipotiazine  (DCI)  \n- Polystyrene  Sulfonate  De Calcium  \n(DCI)  \n- Polystyrene  Sulfonate  De Sodium  \n(DCI)  \n- Pramipexole  (DCI)  \n- Pravastatine  // Fenofibrate  (DCI)  \n- Propericiazine  (DCI)  \n- Propofol  (DCI)  \n- Protamine  (Sulfate)  (DCI)  \n- Prothionamide  (DCI)  \n- Pyridostigmine  (Bromure)  (DCI)  \n- Quetiapine  (DCI)  \n- Quetiapine  (fumarate(  (DCI)  \n- Rabeprazole  (DCI)  \n- Racecadotril  (DCI)  \n- Rifaximine  (DCI)  \n- Rilmenidine  \nDihydrogenophosphate  (DCI)  \n- Risperidone  (DCI)  \n- Ritonavir  (DCI)  \n- Rivastigmine  (DCI)  \n- Rizatriptan  Benzoate  (DCI)  \n- Rocuronium  (Bromure)  (DCI)  \n- Ropivaca\u00efne  (DCI)  \n- Ropinirole  (Chlorhydrate)  (DCI)  - Saccharomyces  Boulardii  (DCI)  \n- Sacubitril  Valsartan  (DCI)  \n- Salbutamol  (DCI)  \n- Sevelamer  Chlorhydrate  (DCI)  \n- Sevoflurane  (DCI)  \n- Sofosbuvir  // Velpatasvir  (DCI)  \n- Spirinolactone  (DCI)  \n- Spores  De Bacillus  Clausii  (DCI)  \n- Spores De Bacillus Clausii  \nMultiresistants Aux Antibiotiques  \n(DCI)  \n- Sugammadex  (Sodique)  (DCI)  \n- Tacrolimus  (DCI)  \n- Tenofovir  (Alafenamide)  \n/Emtricitabine(DCI)  \n- Tenofovir (disoproxil  \nfumarate)/Emtricitabine  \n- Tofacitinib  citrate  (DCI)  \n- Tafluprost  (DCI)  \n- Tamoxifene  (DCI)  \n- Tamsulosine Chlorhydrate //  \nDutasteride  (DCI)  \n- Telmisartan  (DCI)  \n- Telmisartan  // Amlodipine  (DCI)  \n- Telmisartan  // Hydrochlorothiazide  \n(DCI)  \n- Temozolomide  (DCI)  \n- Terazosine  (DCI)  \n- Teriflunomide  (DCI)  \n- Thalidomide  (DCI)  \n- Thiamazole  (DCI)  \n- Ticagrelor  (DCI)  \n- Timolol  (Maleate)  (DCI)  \n- Tiotropium  // Olodaterol  (DCI)  \n- Tiotropium  Bromure  (DCI)  \n- Tiotropium Bromure Monohydrate  \n(DCI)  \n- Tirofiban  (DCI)  \n- Tizanidi ne (DCI)  \n- Tolperisone  (DCI)  \n- Tolterodine  (DCI)  \n- Topiramate  (DCI)  \n- Topotecan  (Chlorhydrate)  (DCI)  \n- Trandolapril  (DCI)", "start_char_idx": 1634, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a735ae87-5856-4bac-8a41-9328a34d6600": {"__data__": {"id_": "a735ae87-5856-4bac-8a41-9328a34d6600", "embedding": null, "metadata": {"page_label": "10", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c08937fc-e903-4f48-bb19-6d119daff916", "node_type": "4", "metadata": {"page_label": "10", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "c7d64078fc0f87b2328c67577f6639a6feabb605ee16f3f83a9aa3df368024d9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f9a1918-fd27-494e-934f-82762c6719e6", "node_type": "1", "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "a748f4b7a806ed4f3aeacd80b7b0d345e68d0e7ca6b816ca778b41af925ed982", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f288b346-600e-4650-ae6f-6865eea21046", "node_type": "1", "metadata": {}, "hash": "c87c1250a510c7307ee698d8f5854cb2878a83c969345b43ba1c6b3e5e7fb0af", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n10 / chap 30   \n - Travoprost  (DCI)  \n- Travoprost  // Timolol  (Maleate)  \n(DCI)  \n- Tretinoine  (DCI)  \n- Triamcinolone  Acetonide  (DCI)  \n- Trimipramine  (Maleate)  (DCI)  \n- Trinitrine  (DCI)  \n- Triptoreline  (DCI)  \n \nc)- des vitamines  suivantes  : - Tropicamide  (DCI)  \n- Tuberculine  Purifiee  (DCI)  \n- Udenafil  (DCI)  \n- Ulipristal  Acetate  (DCI)  \n- Uree  13C (DCI)  \n- Valproate  de Sodium  (DCI)  \n- Venlafaxine  (chlorhydrate)  (DCI)  \n- Varenicline  (Tartrate)  (DCI)  - Verapamil  (Chlorhydrate)  (DCI)  \n- Vinorelbine  (Ditartrate)  (DCI)  \n- Voriconazole  (DCI)  \n- Vortioxetine  (DCI)  \n- Zidovudine  (DCI)  \n- Zofenopril  (DCI)  \n-Zofenopril  Calcium   // \nHydrochlorothiazide  (DCI)  \n- Calcium  // Cholecalciferol  DCI \n- Cholecalciferol  // Carbonate  de calcium  DCI \n- Isotretino\u00efne  \"\" \n- Vitamine  K1 \"\" \nd)- des antidiab\u00e9tiques  suivants  : \n- Dapagliflozine  DCI \n- Dulaglutide  \"\" \n- Empagliflozine  \"\" \n- Linagliptine  \"\" \n- Linagliptine  // Metformine  \"\" \n- Liraglutide  \"\" \n- Metformine  // Glibenclamide  \"\" \n- Saxagliptine  \"\" \n- Sitagliptine  \"\" \n- Sitagliptine  // Metformine  \"\" \n- Vildagliptine  \"\" \n- Vildagliptine/  Metformine  \"\" \n5/ bis.- Ne rentrent  au n\u00b0 3004.90.00.75  que les m\u00e9dicaments  contenant  : \na)- les DCI suivantes : \n \n- Escitalopram  DCI \n- Albendazole  \"\" \n- Alpha -Amylase  \"\" \n- Anastrozole  \"\" \n- Aripiprazole  \"\" \n- Bicarbonate  De Sodium  \"\" \n- Chondroitine  Sulfate  Sodique  \"\" \n- Etoricoxib  \"\" \n- Lamotrigine  \"\" \n- Paroxetine  \"\" \n- Rivaroxaban  \"\" \n- Rosuvastatine  \"\" \n- Tadalafil  \"\" \n- Valsartan  \"\" \n- valsartan//  hydrochlorothiazide  \"\" \n- Clomifene  Citrate  \"\" \n- Pregabaline  \"\" \n5/ter. - Ne rentrent  au n\u00b0 3004.90.00.80  que les m\u00e9dicaments  contenant:  \n- Aciclovir  DCI  \n- Amisulpride   \"\" \n- Atorvastatine  \n- Carvedilol  \"\" \n\"\"  \n- Clopidogrel  \"\"  \n- Diclof\u00e9nac  \n- Diltiazem  (Chlorhydrate)  \"\" \n\"\"", "start_char_idx": 0, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f288b346-600e-4650-ae6f-6865eea21046": {"__data__": {"id_": "f288b346-600e-4650-ae6f-6865eea21046", "embedding": null, "metadata": {"page_label": "11", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "15b9fb3b-eb73-4a12-ba17-01d77f0b9c21", "node_type": "4", "metadata": {"page_label": "11", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "34fba63adaf9f839c554141e668c68e0ccbc6a502561b9e6798684401312a93a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a735ae87-5856-4bac-8a41-9328a34d6600", "node_type": "1", "metadata": {"page_label": "10", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "44ba02235985f08aa45b955290b65e8119c3a15ed675dc2b8b87515868ba86f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f2d24db-459c-44e7-b640-64cf0d4afcdf", "node_type": "1", "metadata": {}, "hash": "807ef1537c2574d32b3a72cd6341234bc2852b92ab9e406bc48b06ec7c76c5c2", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  MAJ  juillet  2023  \n11 / chap  30  \n  \n- Donepezil  \"\" \n- Enalapril  (Maleate)  \"\" \n- Esomeprazole  Magnesium  \"\" \n- Irbesartan  // Hydrochlorothiazide  \"\" \n- Letrozole  \"\" \n- Methyldopa  \"\" \n- M\u00e9tronidazole  \"\" \n- Olanzapine  \"\" \n- Piroxicam  \"\" \n- Pyrazinamide  \"\" \n- Repaglinide  \"\" \n- Solifenacine  Succinate  \"\" \n- Trolamine  \"\" \n \n6/ Ne rentrent  au n\u00b0 3003.90.94.00  que les m\u00e9dicaments  antidiab\u00e9tiques  suivants:  \na- Biguanides  (activateurs  de l\u2019AMP -kinase)  \nMetformine  (DCI)  \nb- Sulfonylur\u00e9es  (bloqueurs  des cannaux  KATP  membranaires  des cellules  b\u00e9ta  \nGlibenclamide  DCI \nGliclazide  \u201c \nGlim\u00e9piride  \u201c \nGlipizide  \u201c \nc- Glinides  (bloqueurs  des canaux  KATP  membranaires  des cellules  b\u00e9ta  \nNatl\u00e9glinide  (DCI)  \nR\u00e9paglinide  \u201c \nd- Gliptines (inibiteurs de la diperptidylpeptidase -4 ou DPP -4) \nSitagliptine  (DCI)  \nVildagliptine  \u201c \nSaxagliptine  \u201c \nLinagliptine  \u201c \ne- Incr\u00e9tinomim\u00e9tiques  (agonistes/analogues  du GLP-1) \nLiraglutide  (DCI)  \nDulaglutide  \u201c \nf- Gliflozines  (Inibiteurs  du SGLT2)  \nCanagliflozine  (DCI)  \nDapagliflozine  \u201c \nEmpagliflozine  \u201c \ng- Inibiteurs  des alpha  glucosidases  (DCI)  \nAcarbose   \u201c", "start_char_idx": 0, "end_char_idx": 1185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f2d24db-459c-44e7-b640-64cf0d4afcdf": {"__data__": {"id_": "7f2d24db-459c-44e7-b640-64cf0d4afcdf", "embedding": null, "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "12daa772-f893-4d04-8a90-da10d155e865", "node_type": "4", "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "60ecb2196d4a6411ef02f3ddddffb0eb64dcec838be367baa0fff052ae62ebc2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f288b346-600e-4650-ae6f-6865eea21046", "node_type": "1", "metadata": {"page_label": "11", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "44b0632f7d40e30b4b08d2c2e905ad7ab134c7d4a39276c253219f27db073c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08524250-c551-4e96-ab89-ea22c02f09ef", "node_type": "1", "metadata": {}, "hash": "00b784e57669a6c4c576bd7760edeff2f5bc554d43f7958aa49ad635d5b4c2a0", "class_name": "RelatedNodeInfo"}}, "text": "l\u00e9mentaires   \n \n \nCodification   \nD\u00e9signation  des Produits  \nDroit  \nd\u2019Importation  \nUnit\u00e9  \nde Quantit\u00e9  \nNormalis\u00e9e  \n \nUnit\u00e9s  Comp - \n30.01     Glandes  et autres  organes  \u00e0 usages  opoth\u00e9rapiques, \u00e0  l\u2019\u00e9tat  \ndess\u00e9ch\u00e9, m\u00eame pulv\u00e9ris\u00e9s; extraits, \u00e0 usages opoth\u00e9rapiques,  \nde glandes ou d\u2019autres organes ou de  leurs s\u00e9cr\u00e9tions; h\u00e9parine  \net ses sels; autres substances humaines ou animales pr\u00e9par\u00e9es \u00e0  \ndes fins th\u00e9rapeutiques ou prophylactiques non d\u00e9nomm\u00e9es ni  \ncomprises  ailleurs.     \n8 3001.20  00 00 \u2013 Extraits  de glandes  ou d\u2019autres organes ou  de leurs s\u00e9cr\u00e9tions  . 2,5 kg \u2013 \n 3001.90  00  \u2013 Autres     \n   10 \u2013 \u2013 \u2013 glandes  et autres organes  \u00e0 usages  opoth\u00e9rapiques, \u00e0 l\u2019\u00e9tat  dess\u00e9ch\u00e9,     \n    m\u00eame  pulv\u00e9ris\u00e9s  .........................................................................................  2,5 kg \u2013 \n    \u2013 \u2013 \u2013 heparine  et ses  sels :    \n5   21 \u2013 \u2013 \u2013  \u2013  \u00e9noxaparine  ...............................................................................................  2,5 kg _ \n5   29 \u2013 \u2013 \u2013 \u2013 autres  .........................................................................................................  2,5 kg _ \n    \u2013 \u2013 \u2013 morceaux  d\u2019os,  organes  et les autres  tissus  humains  ou animaux, vivants  \nou conserv\u00e9s, propres  \u00e0 la r\u00e9alisation  des greffes  ou d\u2019implants  permanents:     \n8  31 \u2013 \u2013 \u2013 \u2013 corn\u00e9e  ........................................................................................................  2,5 kg _ \n8  32 \u2013 \u2013 \u2013 \u2013 moelles.......................................................................................................  2,5 kg _ \n8  33 \u2013 \u2013 \u2013 \u2013 coeurs  ........................................................................................................  2,5 kg _ \n8  34 \u2013 \u2013 \u2013  \u2013  reins  ...........................................................................................................  2,5 kg _ \n8  35 \u2013 \u2013 \u2013 \u2013 foies  ...........................................................................................................  2,5 kg _ \n8  38 \u2013 \u2013 \u2013 \u2013 autres  .........................................................................................................  2,5 kg _ \n8  90 \u2013 \u2013 \u2013 autres............................................................................................................  2,5 kg \u2013 \n 30.02   Sang humain; sang animal pr\u00e9par\u00e9 en vue d\u2019usages th\u00e9rapeutiques,  \nprophylactiques ou de diagnostic; antis\u00e9rums, autres fractions du  \nsang et  produits  immunologiques,  m\u00eame  modifi\u00e9s  ou obtenus  par \nvoie biotechnologiques;  vaccins, toxines, cultures de micro - \norganismes (\u00e0 l\u2019exclusion des levures) et produits similaires;  \ncultures  de cellules,  m\u00eame  modifi\u00e9es.", "start_char_idx": 2, "end_char_idx": 2689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08524250-c551-4e96-ab89-ea22c02f09ef": {"__data__": {"id_": "08524250-c551-4e96-ab89-ea22c02f09ef", "embedding": null, "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "12daa772-f893-4d04-8a90-da10d155e865", "node_type": "4", "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "60ecb2196d4a6411ef02f3ddddffb0eb64dcec838be367baa0fff052ae62ebc2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f2d24db-459c-44e7-b640-64cf0d4afcdf", "node_type": "1", "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "7ff405bfef81cb4aea8d1c1ca0d7386522475a38d7252d8ff2c4f45e1bebbd46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fa8bb7b-21c1-4ebb-9eb3-db940d249f21", "node_type": "1", "metadata": {}, "hash": "3787dd5cd9001f14138d559e54de690994ef91ee586477b22a5a0cf344319102", "class_name": "RelatedNodeInfo"}}, "text": "\u2013 Antis\u00e9rums,  autres  fractions  du sang  et produits  immunologiques  \nm\u00eame  modifi\u00e9s  ou obtenus par  voie biotechnologiques :     \n 3002.12    \u2013 \u2013 Antis\u00e9rums  et autres  fractions  du sang     \n5  10 00 \u2013 \u2013 \u2013 h\u00e9moglobine,  globulines  du sang  et s\u00e9rums  globulines...............................  2,5 kg \u2013 \n8  20 00 \u2013 \u2013 \u2013 s\u00e9rums  normaux  et s\u00e9rums  sp\u00e9cifiques.......................................................  2,5 kg \u2013 \n    \u2013 \u2013 \u2013 autres  :    \n8  92 00 \u2013 \u2013  \u2013 \u2013 d\u2019origine  animale  .......................................................................................  2,5 kg \u2013 \n  98  \u2013 \u2013 \u2013 \u2013 autres :     \n8   10 \u2013 \u2013 \u2013 \u2013 \u2013 conditionn\u00e9s  pour la vente  au d\u00e9tail  .......................................................  2,5 kg \u2013 \n8   90 \u2013 \u2013 \u2013 \u2013 \u2013 non conditionn\u00e9s  pour la  vente  au d\u00e9tail  ...............................................  2,5 kg \u2013 \n8 3002.13  00 00 \u2013 \u2013 Produits  immunologiques,  non m\u00e9lang\u00e9s  et ni pr\u00e9sent\u00e9s  sous     \nforme  de doses,  ni conditionn\u00e9s  pour  la vente  au d\u00e9tail  ............  2,5 kg \u2013 \n8 3002.14  00 00 \u2013 \u2013 Produits  immunologiques,  m\u00e9lang\u00e9s  et non pr\u00e9sent\u00e9s  sous  \nforme  de doses,  ni conditionn\u00e9s  pour  la vente  au d\u00e9tail  ............   \n2,5  \nkg  \n\u2013 \n8 3002.15  00 00 \u2013 \u2013 Produits  immunologiques,  pr\u00e9sent\u00e9s  sous  forme  de doses,  ou \nconditionn\u00e9s  pour  la vente  au d\u00e9tail  ............................................   \n2,5  \nkg  \n\u2013 \n    \u2013 Vaccins,  toxines,  cultures  de micro -organismes  (\u00e0 l\u2019exclusion  \ndes levures)  et produits  similaires:     \n8 3002.41  00 00 \u2013 \u2013 Vaccins  pour  la m\u00e9decine  humaine  ...................................................  2,5 kg \u2013 \n8 3002.42    \u2013 \u2013 Vaccins pour  la m\u00e9decine v\u00e9t\u00e9rinaire     \n8  10 00 \u2013 \u2013 \u2013 vaccins  antiaphteux......................................................................................  10 kg \u2013 \n1 / Chap  30 \nEdition  1er janvier  2022  TARIF  DES DROITS  DE DOUANE  A L\u2019IMPORTATION", "start_char_idx": 2698, "end_char_idx": 4624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fa8bb7b-21c1-4ebb-9eb3-db940d249f21": {"__data__": {"id_": "8fa8bb7b-21c1-4ebb-9eb3-db940d249f21", "embedding": null, "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c28235bd-959f-47d2-aecb-f81ceee62ef2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "82818fef7926d6564009ee8b69f702617195753fbeb09c73b2043fc2c611b87d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08524250-c551-4e96-ab89-ea22c02f09ef", "node_type": "1", "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "804efe3b1948f7bc1c143ab0ca3e20ce4e52e9f0792d9d9c2860fd81d3b19441", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6d427fa-d589-42f6-8a51-a53a341c1b44", "node_type": "1", "metadata": {}, "hash": "0620fa05fa0eb21c3920274e5abd83d22018eac3b9ab5ee7bf55013497b73698", "class_name": "RelatedNodeInfo"}}, "text": "2 / Chap 30   \n \n \nCodification   \nD\u00e9signation  des Produits  \nDroit  \nd\u2019Importation  \nUnit\u00e9  \nde Quantit\u00e9  \nNormalis\u00e9e  \n \nUnit\u00e9s Comp - \nl\u00e9mentaires  \n \n8    \n91  \n00 \u2013 \u2013 \u2013 autres :  \n\u2013 \u2013 \u2013 \u2013 vaccins vis\u00e9s \u00e0  la note compl\u00e9mentaire n\u00b01  du pr\u00e9sent  Chapitre  ...........   \n30  \nkg  \n\u2013 \n8   99 00 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  2,5 kg \u2013 \n  3002.49  00  \u2013 \u2013 Autres     \n \n8     \n11 \u2013 \u2013 \u2013 toxines:  \n\u2013 \u2013 \u2013 \u2013 saxitoxine  d\u2019origine  animale  .......................................................................   \n2,5  \nkg  \n\u2013 \n8    12 \u2013 \u2013 \u2013 \u2013 ricine  ..........................................................................................................  2,5 kg \u2013 \n8 \n \n8    19 \n \n21 \u2013 \u2013 \u2013 \u2013 autres.........................................................................................................  \n\u2013 \u2013 \u2013 cultures  de micro -organismes  (\u00e0 l\u2019exclusion  des levures):  \n\u2013 \u2013  \u2013 \u2013 ferments  lactiques  ......................................................................................  2,5 \n \n2,5 kg \n \nkg \u2013 \n \n\u2013 \n8    29 \u2013 \u2013 \u2013 \u2013 autres.........................................................................................................  2,5 kg \u2013 \n8 \n \n8    30 \n \n91 \u2013 \u2013 \u2013 virus  humains,  animaux  ou v\u00e9g\u00e9taux,  ainsi que les antivirus  ......................  \n\u2013 \u2013 \u2013 autres:  \n\u2013 \u2013 \u2013 \u2013 d\u2019origine  animale  .......................................................................................  2,5 \n \n2,5 kg \n \nkg \u2013 \n \n\u2013 \n8    99 \u2013 \u2013 \u2013 \u2013 autres.........................................................................................................  2,5 kg \u2013 \n     \u2013 Cultures  de cellules,  m\u00eame  modifi\u00e9es:     \n8  3002.51  00 00 \u2013 \u2013 Produits  de th\u00e9rapie  cellulaire.......................................................  2,5 kg \u2013 \n8  3002.59  00 00 \u2013 \u2013 Autres...............................................................................................  2,5 kg \u2013 \n  3002.90    \u2013 Autres     \n8   10 00 \u2013 \u2013 \u2013 sans  humain.................................................................................................  2,5 kg \u2013 \n8   20 00 \u2013 \u2013 \u2013 sang  animal pr\u00e9par\u00e9 en  vue d\u2019usages th\u00e9rapeutiques,  prophylactiques ou  \nde  diagnostic  ................................................................................................   \n2,5  \nkg  \n\u2013 \n8   90 00 \u2013 \u2013 \u2013  autres  ..........................................................................................................  2,5 kg \u2013 \n 30.03     M\u00e9dicaments (\u00e0 l\u2019exclusion des produits des n\u00b0s 30.02, 30.05 ou  \n30.06) constitu\u00e9s par des produits m\u00e9lang\u00e9s entre eux, pr\u00e9par\u00e9s \u00e0  \ndes fins th\u00e9rapeutiques  ou prophylactiques,  mais  ni pr\u00e9sent\u00e9s  sous  \nforme  de doses,  ni conditionn\u00e9s pour  la vente au d\u00e9tail.", "start_char_idx": 2, "end_char_idx": 2791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6d427fa-d589-42f6-8a51-a53a341c1b44": {"__data__": {"id_": "d6d427fa-d589-42f6-8a51-a53a341c1b44", "embedding": null, "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c28235bd-959f-47d2-aecb-f81ceee62ef2", "node_type": "4", "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "82818fef7926d6564009ee8b69f702617195753fbeb09c73b2043fc2c611b87d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fa8bb7b-21c1-4ebb-9eb3-db940d249f21", "node_type": "1", "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "f13c7495a05fe34c8ec4d7a480ca0229d74131551a4cd034a19e1435af176562", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fa79cc9-dd92-483d-a6d2-ba58ff14995f", "node_type": "1", "metadata": {}, "hash": "a234faa3f181110386fd2f1ea8638fe5422c0e116e1da938ab8f31f183978e64", "class_name": "RelatedNodeInfo"}}, "text": "Edition  1er janvier  2022  TARIF  DES DROITS  DE DOUANE  A L\u2019IMPORTATION  \n3003.10  \u2013 Contenant des p\u00e9nicillines ou des d\u00e9riv\u00e9s de ces produits, \u00e0  \nstructure d\u2019acide p\u00e9nicillanique, ou des streptomycines ou des  \nd\u00e9riv\u00e9s  de ces produits  \n8  10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n \n8  90  \n10 \u2013 \u2013 \u2013 autres :  \n\u2013 \u2013 \u2013 \u2013 autres, vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 2a du pr\u00e9sent chapitre............   \n2.5  \nkg  \n\u2013 \n8   90 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  17,5 kg \u2013 \n \n3003.20    \n\u2013 Autres,  contenant  des antibiotiques     \n8  \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n \n8  90  \n10 \u2013 \u2013 \u2013 autres :  \n\u2013 \u2013 \u2013 \u2013 autres, vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 2b du pr\u00e9sent chapitre............   \n2.5  \nkg  \n\u2013 \n8   90 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  17,5 kg \u2013 \n    \n\u2013 Autres, contenant  des hormones  ou d\u2019autres  produits  du n\u00b0 29.37:     \n  \n3003.31   \n00   \n\u2013 \u2013 Contenant  de l\u2019insuline     \n8   \n10 \u2013 \u2013 \u2013 vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 3a du pr\u00e9sent  chapitre  ..........................  2.5 kg \u2013 \n8   90 \u2013 \u2013 \u2013 autres  ...........................................................................................................  10 kg \u2013", "start_char_idx": 2849, "end_char_idx": 4340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fa79cc9-dd92-483d-a6d2-ba58ff14995f": {"__data__": {"id_": "6fa79cc9-dd92-483d-a6d2-ba58ff14995f", "embedding": null, "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "be7736d9-8aa3-4df3-bfdd-41d3c15ad776", "node_type": "4", "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "02ffc062bcfe4de07db70a270afec7d583f87b12c2bd323b5ebb202ee38431fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6d427fa-d589-42f6-8a51-a53a341c1b44", "node_type": "1", "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "08dd3444ecd12b0b22f0b74ec94859200feba1c1c3c44972a1978fedde536820", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adbfc273-47a6-4b05-b69c-73991d9fedc6", "node_type": "1", "metadata": {}, "hash": "e9626c6a67c3368e552ede3c214a97da231b52ed969d7eede69d451d0c88c58a", "class_name": "RelatedNodeInfo"}}, "text": "Codification   \nD\u00e9signation  des Produits  \nDroit  \nd\u2019Importation  \nUnit\u00e9  \nde Quantit\u00e9  \nNormalis\u00e9e  \n \nUnit\u00e9s Comp - \nl\u00e9mentaires  \n  3003.39    \u2013 \u2013 Autres     \n8   10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire........................................................................  10 kg \u2013 \n   80  \u2013 \u2013 \u2013 autres :     \n8    10 \u2013 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 3b ou 3c pr\u00e9sent  chapitre.......  2,5 kg \u2013 \n8    90 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  17,5 kg \u2013 \n     \u2013 Autres,  contenant  des alcalo\u00efdes  ou leurs  d\u00e9riv\u00e9s  :    \n  \n3003.41    \n\u2013 \u2013 Contenant  de l\u2019\u00e9ph\u00e9drine  ou ses sels     \n8   \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire........................................................................  10 kg \u2013 \n8   90 00 \u2013 \u2013 \u2013 autres  ..................................................................................................................  2,5 kg \u2013 \n  \n3003.42    \n\u2013 \u2013 Contenant  de la pseudo\u00e9ph\u00e9drine  (DCI)  ou ses sels     \n8   \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire........................................................................  10 kg \u2013 \n8   90 00 \u2013 \u2013 \u2013 autres  ..................................................................................................................  17,5 kg \u2013 \n  \n3003.43    \n\u2013 \u2013 Contenant  de la nor\u00e9ph\u00e9drine  ou ses  sels     \n8   \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire........................................................................  10 kg \u2013 \n8   90 00 \u2013 \u2013 \u2013 autres  ..................................................................................................................  2,5 kg \u2013 \n  \n3003.49    \n\u2013 \u2013 Autres     \n8   \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire........................................................................  10 kg \u2013 \n   90  \u2013 \u2013 \u2013 autres :     \n8    10 \u2013 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 4 pr\u00e9sent  chapitre...................  2,5 kg \u2013 \n8    90 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  17,5 kg \u2013 \n  \n3003.60    \n\u2013 Autres,  contenant  des principes  actifs contre  le paludisme  \nd\u00e9crits  dans la  Note 2  de sous -positions du pr\u00e9sent  Chapitre     \n8   \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire.........................................................................  10 kg \u2013 \n   80  \u2013 \u2013 \u2013 autres:     \n8    10 \u2013 \u2013 \u2013 \u2013 chloroquine  .......................................................................................................  17,5 kg \u2013 \n8    90 \u2013 \u2013 \u2013 \u2013 autres  .........................................................................................................  2,5 kg \u2013 \n  \n3003.90    \n\u2013 Autres     \n8   \n10 00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n     \u2013 \u2013 \u2013 autres :     \n8   94 00 \u2013 \u2013 \u2013 \u2013 m\u00e9dicaments vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b06 du pr\u00e9sent  Chapitre  ... 2,5 kg \u2013 \n8   95 00 \u2013 \u2013 \u2013 \u2013 autres, vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b05 du pr\u00e9sent  Chapitre.............  2,5 kg \u2013 \n8   98 00 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  17,5 kg \u2013 \n \n30.04     \nM\u00e9dicaments  (\u00e0 l\u2019exclusion  des produits  des n\u00b0s 30.02,  30.05  ou    \n     30.06)  constitu\u00e9s  par des produits  m\u00e9lang\u00e9s  ou non m\u00e9lang\u00e9s,     \n     pr\u00e9par\u00e9s \u00e0  des fins th\u00e9rapeutiques  ou prophylactiques,  pr\u00e9sent\u00e9s     \n     sous  forme  de doses  (y compris  ceux  destin\u00e9s  \u00e0 \u00eatre administr\u00e9s     \n     par voie  percutan\u00e9e)  ou conditionn\u00e9s  pour  la vente  au d\u00e9tail.", "start_char_idx": 8, "end_char_idx": 3649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adbfc273-47a6-4b05-b69c-73991d9fedc6": {"__data__": {"id_": "adbfc273-47a6-4b05-b69c-73991d9fedc6", "embedding": null, "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "be7736d9-8aa3-4df3-bfdd-41d3c15ad776", "node_type": "4", "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "02ffc062bcfe4de07db70a270afec7d583f87b12c2bd323b5ebb202ee38431fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fa79cc9-dd92-483d-a6d2-ba58ff14995f", "node_type": "1", "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "db5bf8d84b32b5e29ee0001874a1c7b1acfe0a23a6ae504a7f1b86d89b0f39d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25fa2ce5-52da-46b5-9e68-dcaed4470947", "node_type": "1", "metadata": {}, "hash": "abffd6e077bcda7b199d3141d749b3184ef2f1b3df5a6c1e8209c0016c06788d", "class_name": "RelatedNodeInfo"}}, "text": "3004.10  00  \n\u2013 Contenant  des p\u00e9nicillines  ou des d\u00e9riv\u00e9s  de ces produits,  \u00e0    \n     structure  d\u2019acide  p\u00e9nicillanique,  ou des streptomycines  ou des    \n     d\u00e9riv\u00e9s  de ces produits     \n8 10 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n8 20 \u2013 \u2013 \u2013 autres,  antimitotiques  y compris  les sp\u00e9cialit\u00e9s  des traitements  pr\u00e9op\u00e9ratoires     \n  ou postop\u00e9ratoires  en chimioth\u00e9rapie  ou en radioth\u00e9rapie  ..........................  2,5 kg \u2013 \nEdition  1er janvier  2022  TARIF  DES DROITS  DE DOUANE  A L\u2019IMPORTATION  \n3 / Chap  30", "start_char_idx": 3658, "end_char_idx": 4267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25fa2ce5-52da-46b5-9e68-dcaed4470947": {"__data__": {"id_": "25fa2ce5-52da-46b5-9e68-dcaed4470947", "embedding": null, "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "446dfa36-0794-45b9-942f-cdd0f05f6b09", "node_type": "4", "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "8435ac87a8bb69fc5217c07fae7ff98104a96e0f80ab7809c5c35fcbc58a35cb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adbfc273-47a6-4b05-b69c-73991d9fedc6", "node_type": "1", "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "cebd0dc1ec3230b0b4c0859998b81bb515b2c4cffe81624cca5200882c526d0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eee149dc-c107-4657-a3cc-08f8e133ae18", "node_type": "1", "metadata": {}, "hash": "ff0a3f7be0ffbc579752438d3985eda6343c18f553473677c2247420d96f1a8a", "class_name": "RelatedNodeInfo"}}, "text": "Codification  D\u00e9signation  des Produits  \n \n \n8 40 \n8 50 \n8 85  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b02a 2) du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b02a 3) du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres  .   \n2,5 kg \u2013 \n10 kg \u2013 \n30 kg \u2013 \n \n3004.20  00 \u2013 Autres,  contenant  des antibiotiques  \n \n8 10 \n8 20 \n \n8 50 \n8 60 \n8 65 \n8 85 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .  \n\u2013 \u2013 \u2013 autres, antimitotiques y compris les sp\u00e9cialit\u00e9s des traitements pr\u00e9op\u00e9ratoires  \nou postop\u00e9ratoires  en chimioth\u00e9rapie  ou en radioth\u00e9rapie  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b02b  du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b02bis  du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b02ter  du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres  .  10 kg \u2013 \n \n2,5 kg \u2013 \n2,5 kg \u2013 \n17,5 kg \u2013 \n10 kg \u2013 \n30 kg \u2013 \n \n\u2013 Autres,  contenant  des hormones  ou d\u2019autres  produits  du n\u00b0 29.37:  \n \n3004.31  00 \u2013 \u2013 Contenant  de l\u2019insuline  \n \n8 30 \n8 40 \n8 80 \u2013 \u2013 \u2013 vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03a du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03bis  a) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres  .  2,5 kg \u2013 \n10 kg \u2013 \n30 kg \u2013 \n \n3004.32  00  \n\u2013 \u2013 Contenant  des hormones  corticost\u00e9ro\u00efdes,  leurs  d\u00e9riv\u00e9s  ou \nanalogues  structurels  \n \n8 10 \n8 20 \n \n8 60 \n8 70 \n8 80 \n8 90  \n\u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .  \n\u2013 \u2013 \u2013 autres, antimitotiques y compris les sp\u00e9cialit\u00e9s des traitements pr\u00e9op\u00e9ratoires  \nou postop\u00e9ratoires  en chimioth\u00e9rapie  ou en radioth\u00e9rapie  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03b  du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03bis  b) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03ter  a) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres  .   \n10 kg \u2013 \n \n2,5 kg \u2013 \n2,5 kg \u2013 \n10 kg \u2013 \n17,5 kg \u2013 \n30 kg \u2013 \n \n3004.39  00 \u2013 \u2013 Autres  \n \n8 10 \n8 20 \n \n70 \n8 75 \n8 80 \n8 95 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .  \n\u2013 \u2013 \u2013 autres, antimitotiques y compris les sp\u00e9cialit\u00e9s des traitements pr\u00e9op\u00e9ratoires  \nou postop\u00e9ratoires  en chimioth\u00e9rapie  ou en radioth\u00e9rapie  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03c du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 3bis c) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03ter  b) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres  .  10 kg \u2013 \n \n2,5 kg \u2013 \n2,5 kg \u2013 \n10 kg \u2013 \n17,5 kg \u2013 \n30 kg \u2013 \n \n\u2013 Autres,  contenant  des alcalo\u00efdes  ou leurs  d\u00e9riv\u00e9s  \n \n3004.", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eee149dc-c107-4657-a3cc-08f8e133ae18": {"__data__": {"id_": "eee149dc-c107-4657-a3cc-08f8e133ae18", "embedding": null, "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "446dfa36-0794-45b9-942f-cdd0f05f6b09", "node_type": "4", "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "8435ac87a8bb69fc5217c07fae7ff98104a96e0f80ab7809c5c35fcbc58a35cb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25fa2ce5-52da-46b5-9e68-dcaed4470947", "node_type": "1", "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "f2cc0baefea0e1e3d1246e2ec3d5358927f845a561214726f588ef9494407036", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5ebc1a0-51ae-49ef-9997-98bee85c1d12", "node_type": "1", "metadata": {}, "hash": "de2614b79c02140c7ac047ccbe483abbec412171a1b9995251d37e0eaa18b9cb", "class_name": "RelatedNodeInfo"}}, "text": "antimitotiques y compris les sp\u00e9cialit\u00e9s des traitements pr\u00e9op\u00e9ratoires  \nou postop\u00e9ratoires  en chimioth\u00e9rapie  ou en radioth\u00e9rapie  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03c du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b0 3bis c) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b03ter  b) du pr\u00e9sent  Chapitre  .  \n\u2013 \u2013 \u2013 autres  .  10 kg \u2013 \n \n2,5 kg \u2013 \n2,5 kg \u2013 \n10 kg \u2013 \n17,5 kg \u2013 \n30 kg \u2013 \n \n\u2013 Autres,  contenant  des alcalo\u00efdes  ou leurs  d\u00e9riv\u00e9s  \n \n3004.41  00 \u2013 \u2013 Contenant  de l\u2019\u00e9ph\u00e9drine ou ses sels  \n \n8 10 \n8 30 \n8 80 \n \n3004.42  00 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .  \n\u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note  compl\u00e9mentaire n\u00b0  4 bis  du pr\u00e9sent  Chapitre.  \n\u2013 \u2013 \u2013 autres  .  \n \n\u2013 \u2013 Contenant  de la pseudo\u00e9ph\u00e9drine  (DCI)  ou ses sels  10 kg \u2013 \n10 kg \u2013 \n2,5 kg \u2013 \n \n8 10 \n8 80 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .  \n\u2013 \u2013 \u2013 autres  .  10 kg \u2013 \n17,5 kg \u2013 \n \n3004.43  00 \u2013 \u2013 Contenant  de la nor\u00e9ph\u00e9drine ou ses sels  \n \n8 10 \n8 80 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .  \n\u2013 \u2013 \u2013 autres  .  10 kg \u2013 \n2,5 kg \u2013 \n \n \n \n \n \n4 / Chap 30  \nEdition  1er janvier  2022  TARIF  DES DROITS  DE DOUANE  A L\u2019IMPORTATION  TARIF  Droit  \nd\u2019Importation  \nUnit\u00e9  \nde Quantit\u00e9  \nNormalis\u00e9e  \nUnit\u00e9s Comp - \nl\u00e9mentaires", "start_char_idx": null, "end_char_idx": null, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5ebc1a0-51ae-49ef-9997-98bee85c1d12": {"__data__": {"id_": "c5ebc1a0-51ae-49ef-9997-98bee85c1d12", "embedding": null, "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "036b28b7-3a22-4eaa-aeaf-f623eac2b5bd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "d4f4b110ee9f796480adfd53dad2fe5314190d8d546fc381f57fbcb6a3525b8d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eee149dc-c107-4657-a3cc-08f8e133ae18", "node_type": "1", "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "d01ffe7e622fcb2a915660b616a7d4047dc32485ea31a66c705dcc5265faf1ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c1a2fcd-77d9-46d0-8ec9-b7459e381a33", "node_type": "1", "metadata": {}, "hash": "a92288667bdea34b56dbf53b6dabd8207fb66bd3d12d222f6a31fbe42680a856", "class_name": "RelatedNodeInfo"}}, "text": "Codification   \nD\u00e9signation  des Produits  \nDroit  \nd\u2019Importation  \nUnit\u00e9  \nde Quantit\u00e9  \nNormalis\u00e9e  \n \nUnit\u00e9s Comp - \nl\u00e9mentaires  \n   \n3004.49   \n00   \n\u2013 \u2013 Autres     \n8    \n10 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n8    20 \u2013 \u2013 \u2013 autres,  antimitotiques y  compris  les sp\u00e9cialit\u00e9s  des traitements  pr\u00e9op\u00e9ratoires     \n     ou posteop\u00e9ratoires en  chimioth\u00e9rapie  ou en radioth\u00e9rapie.............................  2,5 kg \u2013 \n    35 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b04 du pr\u00e9sent  Chapitre.................  2,5 kg \u2013 \n8    45 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b04 ter du pr\u00e9sent Chapitre............  17,5 kg \u2013 \n8    80 \u2013 \u2013 \u2013 autres  ...........................................................................................................  30 kg \u2013 \n  \n3004.50  00  \n\u2013 Autres,  contenant  des vitamines ou d\u2019autres  produits  du n\u00b0 29.36     \n8    10 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n     \u2013 \u2013 \u2013 autres:     \n8    81 \u2013 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b05 c du pr\u00e9sent  Chapitre  ..........  2,5 kg \u2013 \n8    89 \u2013 \u2013 \u2013 \u2013 autres.........................................................................................................  30 kg \u2013 \n  3004.60  00  \u2013 Autres,  contenant  des principes  actifs  contre le  paludisme  \nd\u00e9crits  dans  la Note 2  de sous -positions  du pr\u00e9sent  Chapitre     \n8    10 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n     \u2013 \u2013 \u2013 autres:     \n8    40 \u2013 \u2013 \u2013 \u2013 chloroquine................................................................................................  30 kg \u2013 \n8    80 \u2013 \u2013 \u2013 \u2013 autres  ...............................................................................................................  2,5 kg \u2013 \n  3004.90  00  \u2013 Autres     \n8    10 \u2013 \u2013 \u2013 pour la m\u00e9decine  v\u00e9t\u00e9rinaire  .......................................................................  10 kg \u2013 \n8    20 \u2013 \u2013 \u2013 autres,  antimitotiques y  compris  les sp\u00e9cialit\u00e9s  des traitements  pr\u00e9op\u00e9ratoires     \n     ou postop\u00e9ratoires  en chimioth\u00e9rapie  ou en radioth\u00e9rapie  ..........................  2,5 kg \u2013 \n8    70 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b05a  ou 5b ou 5d du pr\u00e9sent     \n     Chapitre........................................................................................................  2,5 kg \u2013 \n8    75 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b05bis  a) du pr\u00e9sent  Chapitre  ........  10 kg \u2013 \n8    80 \u2013 \u2013 \u2013 autres,  vis\u00e9s  \u00e0 la note compl\u00e9mentaire  n\u00b05ter  du pr\u00e9sent  Chapitre.............  17,5 kg \u2013 \n8    90 \u2013 \u2013 \u2013 autres  ...........................................................................................................  30 kg \u2013 \n 30.05   \n \n \n \n \n3005.10   \n \n \n \n \n \n \n \n10  Ouates, gazes, bandes et articles analogues (pansements,  \nsparadraps, sinapismes, par exemple), impr\u00e9gn\u00e9s ou recouverts  \nde substances pharmaceutiques ou conditionn\u00e9s pour la vente au  \nd\u00e9tail  \u00e0 des fins m\u00e9dicales,  chirurgicales,  dentaires  ou v\u00e9t\u00e9rinaires.", "start_char_idx": 8, "end_char_idx": 3198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c1a2fcd-77d9-46d0-8ec9-b7459e381a33": {"__data__": {"id_": "6c1a2fcd-77d9-46d0-8ec9-b7459e381a33", "embedding": null, "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "036b28b7-3a22-4eaa-aeaf-f623eac2b5bd", "node_type": "4", "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "d4f4b110ee9f796480adfd53dad2fe5314190d8d546fc381f57fbcb6a3525b8d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5ebc1a0-51ae-49ef-9997-98bee85c1d12", "node_type": "1", "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "4f988d6f0715795946e11c1fb78011addc04d392ccbc60829fd920a582e13961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "933577b3-4bb7-402a-b64c-dc78c2dae4d3", "node_type": "1", "metadata": {}, "hash": "7d68fff7124229466366d8ff71e6db8368ce60a24a86d4b5a528ffb6ce45361c", "class_name": "RelatedNodeInfo"}}, "text": "\u2013 Pansements  adh\u00e9sifs  et autres  articles  ayant  une couche  adh\u00e9sive  \n \n\u2013 \u2013 \u2013 impr\u00e9gn\u00e9s  ou recouverts  de substances  pharmaceutiques  (y compris  les \ntimbres  transdermiques  ou \"patch\")  :    \n8    10 \u2013 \u2013 \u2013 \u2013 sparadraps  ................................................................................................  2,5 kg \u2013 \n8   90 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  2,5 kg \u2013 \n  90  \u2013 \u2013 \u2013 autres :     \n8   11 \u2013 \u2013 \u2013 \u2013 articles  en ouates  ......................................................................................  30 kg \u2013 \n8   12 \u2013 \u2013 \u2013 \u2013 articles  en gaze  .........................................................................................  30 kg \u2013 \n8   19 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  30 kg \u2013 \n 3005.90    \u2013 Autres     \n8  10 00 \u2013 \u2013 \u2013 impr\u00e9gn\u00e9s  ou reouverts  de substances  pharmaceutiques  ..........................  30 kg \u2013 \n  90  \u2013 \u2013 \u2013 autres :     \n8   11 \u2013 \u2013 \u2013 \u2013 ouates........................................................................................................  30 kg \u2013 \n8   12 \u2013 \u2013 \u2013 \u2013 gazes.........................................................................................................  30 kg \u2013 \n8   13 \u2013 \u2013 \u2013 \u2013 bandes  pl\u00e2tr\u00e9es.........................................................................................  2,5 kg \u2013 \n8   19 \u2013 \u2013 \u2013 \u2013 autres  ........................................................................................................  30 kg \u2013 \nEdition  1er janvier  2022  TARIF  DES DROITS  DE DOUANE  A L\u2019IMPORTATION  TARIF  \n5 / Chap  30", "start_char_idx": 3203, "end_char_idx": 4909, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "933577b3-4bb7-402a-b64c-dc78c2dae4d3": {"__data__": {"id_": "933577b3-4bb7-402a-b64c-dc78c2dae4d3", "embedding": null, "metadata": {"page_label": "17", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c989df6e-8dc3-4754-b2a1-c5bcdfabe0e4", "node_type": "4", "metadata": {"page_label": "17", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "794d60afd735e49f407ff37feffcfd11640d08b6ed572906d6575de26e4b4086", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c1a2fcd-77d9-46d0-8ec9-b7459e381a33", "node_type": "1", "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "3f09ceba6e9c82660046c73894e543aad2c0457a934603e61b0368c575c4d978", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76017ac8-7bd7-47e3-9183-9e63d8547257", "node_type": "1", "metadata": {}, "hash": "d97989ba73c8db67ce0a1595ae8afdf6fb29e8f0b64052eebfb63f2c6e26559a", "class_name": "RelatedNodeInfo"}}, "text": "Codification  D\u00e9signation  des Produits  \n \n \n30.06  Pr\u00e9parations  et articles  pharmaceutiques  vis\u00e9s  \u00e0 la Note  4 du \npr\u00e9sent  Chapitre.  \n \n3006.10  \u2013 Catguts  st\u00e9riles,  ligatures  st \u00e9riles  similaires  pour  sutures  \nchirurgicales  ( y compris  les fils r\u00e9sorbables  st\u00e9riles  pour  \nla chirurgie  ou l\u2019art dentaire)  et adh\u00e9sifs  st\u00e9riles  pour  tissus  \norganiques  utilis\u00e9s en chirurgie pour  refermer les plaies;  \nlaminaires st\u00e9riles;  h\u00e9mostatiques r\u00e9sorbables st\u00e9riles pour  la \nchirurgie  ou l\u2019art dentaire  ; barri\u00e8res  anti - adh\u00e9rence  st\u00e9riles  \npour  la chirurgie  ou l \u2019 art dentaire,  r\u00e9sorbables  ou non.", "start_char_idx": 6, "end_char_idx": 634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76017ac8-7bd7-47e3-9183-9e63d8547257": {"__data__": {"id_": "76017ac8-7bd7-47e3-9183-9e63d8547257", "embedding": null, "metadata": {"page_label": "17", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date"], "relationships": {"1": {"node_id": "c989df6e-8dc3-4754-b2a1-c5bcdfabe0e4", "node_type": "4", "metadata": {"page_label": "17", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "794d60afd735e49f407ff37feffcfd11640d08b6ed572906d6575de26e4b4086", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "933577b3-4bb7-402a-b64c-dc78c2dae4d3", "node_type": "1", "metadata": {"page_label": "17", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}, "hash": "68740f808aa5bf200d04cd1ec6461cbb7dcd298346fca2747729727430ca6737", "class_name": "RelatedNodeInfo"}}, "text": "3006.10  \u2013 Catguts  st\u00e9riles,  ligatures  st \u00e9riles  similaires  pour  sutures  \nchirurgicales  ( y compris  les fils r\u00e9sorbables  st\u00e9riles  pour  \nla chirurgie  ou l\u2019art dentaire)  et adh\u00e9sifs  st\u00e9riles  pour  tissus  \norganiques  utilis\u00e9s en chirurgie pour  refermer les plaies;  \nlaminaires st\u00e9riles;  h\u00e9mostatiques r\u00e9sorbables st\u00e9riles pour  la \nchirurgie  ou l\u2019art dentaire  ; barri\u00e8res  anti - adh\u00e9rence  st\u00e9riles  \npour  la chirurgie  ou l \u2019 art dentaire,  r\u00e9sorbables  ou non.  \n \n8 10 00 \n8 50 00 \n \n8 80 00 \u2013 \u2013 \u2013 catguts  st\u00e9riles  .............................................................................................  \n\u2013 \u2013 \u2013 ligatures  st\u00e9riles  similaires  pour sutures  chirurgicales  (y compirs  les fils \nr\u00e9sorbables  st\u00e9riles  pour la chirurgie  ou l\u2019art dentaire)  ................................  \n\u2013 \u2013 \u2013 autres  ...........................................................................................................  30 kg \u2013 \n \n30 kg \u2013 \n2,5 kg \u2013 \n \n3006.30  \u2013 Pr\u00e9parations  opacifiantes pour examens radiographiques; r\u00e9actifs  \nde diagnostic con\u00e7us pour  \u00eatre employ\u00e9s sur  le patient  \n \n8 10 00 \n8 20 00 \u2013 \u2013 \u2013 pr\u00e9parations  opacifiantes  pour examens  radiographiques  .........................  \n\u2013 \u2013 \u2013 r\u00e9actifs  de diagnostic  con\u00e7us  pour \u00eatre employ\u00e9s  sur le  patient.................  2,5 kg \u2013 \n2,5 kg \u2013 \n \n3006.40  \u2013 Ciments  et autres  produits  d\u2019obturation  dentaire;  ciments  pour  la \nr\u00e9fection  osseuse  \n \n8 10 00 \n8 20 00 \u2013 \u2013 \u2013 ciments  et autres  produits  d\u2019obturation  dentaire  ..........................................  \n\u2013 \u2013 \u2013 ciments  pour la r\u00e9fection  osseuse  ...............................................................  2,5 kg \u2013 \n2,5 kg \u2013 \n \n8 3006.50  00 00 \u2013 Trousses  et bo\u00eetes  de pharmacie  garnies,  pour  soins  de premi\u00e8re  \nurgence  .........................................................................................................   \n2,5 kg \u2013 \n \n3006.60  \u2013 Pr\u00e9parations  chimiques  contraceptives  \u00e0 base  d\u2019hormones,  \nd\u2019autres  produits  du n\u00b0 29.37  ou de spermicides  \n \n8 10 00 \n8 90 00 \u2013 \u2013 \u2013 pr\u00e9parations  chimiques  contraceptives  \u00e0 base  d\u2019hormones  .......................  \n\u2013 \u2013 \u2013 autres  ...........................................................................................................  2,5 kg \u2013 \n2,5 kg \u2013 \n \n8 3006.70  00 00 \u2013 Pr\u00e9parations pr\u00e9sent\u00e9es sous forme de gel con\u00e7ues pour \u00eatre  \nutilis\u00e9es en m\u00e9decine humaine ou v\u00e9t\u00e9rinaire comme lubrifiant  \npour certaines parties du corps lors des op\u00e9rations chirurgicales  \nou des examens  m\u00e9dicaux ou comme  agent de  couplage  entre  \nle corps  et les instruments  m\u00e9dicaux ................................ .............   \n \n \n \n \n2,5 kg \u2013 \n \n\u2013 Autres:  \n \n8 3006.91  00 00 \u2013 \u2013 Appareillages  identifiables de  stomie  .........................................  2,5 kg \u2013 \n \n8 3006.92  00 00 \u2013 \u2013 D\u00e9chets  pharmaceutiques  ...........................................................  2,5 kg \u2013 \n \n3006.93  00 \u2013 \u2013 Placebos  et trouses  pour  essais  cliniques  masqu\u00e9s  (ou \u00e0 \ndouble  insu),  destin\u00e9s  \u00e0 un essai  clinique  reconnu,  pr\u00e9sent\u00e9s  \nsous  forme de  doses  \n \n8 10 \n8 20 \u2013 \u2013 \u2013 placebos  ......................................................................................................  \n\u2013 \u2013 \u2013 trousses........................................................................................................  2,5 kg \u2013 \n2,5 kg \u2013 \n \n \n \n \n \n \n \n \n \n6 / Chap 30  \nEdition  1er Janvier  2022  TARIF  DES DROITS  DE DOUANE  A L\u2019IMPORTATION  Droit  \nd\u2019Importation  \nUnit\u00e9  \nde Quantit\u00e9  \nNormalis\u00e9e  \nUnit\u00e9s Comp - \nl\u00e9mentaires", "start_char_idx": 150, "end_char_idx": 3735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"d7c8fdab-09be-4f44-8b48-7097025cbefe": {"doc_hash": "bb6e465ca999831808e8c4603723c7d1ab5da4adabe77bbdc049315e3d6a0baa", "ref_doc_id": "0aedb42c-40a9-4e23-ae4d-6349762fd4ae"}, "8d66aba3-781b-4f65-9789-4c0d52d205c5": {"doc_hash": "be230d9697c9c13d8a1e32ce5e5db81c394659bb365f2e9df27e393fbebb5ae0", "ref_doc_id": "0aedb42c-40a9-4e23-ae4d-6349762fd4ae"}, "6e076a90-493a-462f-a532-92b9a044b5b1": {"doc_hash": "e9263d0fff0709aee581d9c36d334795db272569b7d354159d1f59f963c4b03d", "ref_doc_id": "b831dd29-def8-47cb-ae7c-a20123db8836"}, "200941cd-78f6-4e4a-9e32-ee17811558d0": {"doc_hash": "54a1d4734f2b257d0de3deddcee765a6c69af8d55e63745432e90606158762a9", "ref_doc_id": "b831dd29-def8-47cb-ae7c-a20123db8836"}, "606b603e-0be4-41d6-a28a-e0a3f8642be3": {"doc_hash": "6920dc3c31a9b8d695de566f1e27f268aa378f49690b7d28d8334a04656fa0c4", "ref_doc_id": "081e806b-0489-4f0a-824d-f759cfec0321"}, "30f08385-9974-435a-aeec-d28425c18c4e": {"doc_hash": "49439618a63ac6556cfe361ebfa83f9c6e9a1f529c31cb4c9a9409653d938f24", "ref_doc_id": "76848cfd-028d-4b50-b0a1-7dfdf6feb893"}, "c1d209c4-8132-4cbd-9ea6-90c8b1f8c5ed": {"doc_hash": "7b0700f4928914a7fe08d5d7b342f56e0011b5fd87ad9a2af8e73c3f6e3e42ce", "ref_doc_id": "a62a1bc9-e80e-4dd8-9f88-2d7d4bff63a5"}, "c989c2c9-e961-45a3-b871-14cf0e2906c4": {"doc_hash": "c5d1e1f40a789bf411357dca3d8c1e349861ea2fb250bbe327950e44cc207947", "ref_doc_id": "306caaa3-2674-4c00-a625-ee0abca82678"}, "059a7f70-4a8a-4d82-ac8d-e6abad27510a": {"doc_hash": "e64162913cfb815077056743621e1f88b2c7c775c4dad3e4ec8345eae258b68f", "ref_doc_id": "306caaa3-2674-4c00-a625-ee0abca82678"}, "5c5d0ff4-6a3b-4039-99d5-f188e6fa1281": {"doc_hash": "73e91c525e33bc77ede2007c995d56a63c105cf9b1a64137c44947e6eef4c2cc", "ref_doc_id": "4c695a13-8013-42b2-ac4d-90a6443e5881"}, "fe1b3b08-1b5d-49b2-ba35-f8b9e30406d7": {"doc_hash": "56e9666ad2b3a05c163c47b78645f0f45b634d687cac9648468be34f8acad645", "ref_doc_id": "4c695a13-8013-42b2-ac4d-90a6443e5881"}, "1f9530ce-d89f-4c87-9d47-d1a26969abf6": {"doc_hash": "534912f537f804102b7fd4f6c6902b9809a3ee0563d565539e801cfe477721c3", "ref_doc_id": "4c695a13-8013-42b2-ac4d-90a6443e5881"}, "1ecb6cb2-e7dd-4680-9233-fc83d5b5da8b": {"doc_hash": "8b5da27955a5118e4268c178a860cf67e7cf90da11acd248c649e6bc5f8e58cf", "ref_doc_id": "13682a38-9c55-46cf-b46c-68a644d4a2fc"}, "dd9cedc5-6eec-4e8d-a91f-48eae517fee7": {"doc_hash": "45ff9799ba38014b01b063a95d2b9bf8a22db651125597934092e772cd6340a4", "ref_doc_id": "13682a38-9c55-46cf-b46c-68a644d4a2fc"}, "1bb4d472-fc1a-450d-b588-eda53e5f3f02": {"doc_hash": "581344a0a4368ac86ff786e9751e6c9388bfda8baf32379966b4635237799026", "ref_doc_id": "13682a38-9c55-46cf-b46c-68a644d4a2fc"}, "acecd13e-28ee-49a8-862d-cd7cfb6a2972": {"doc_hash": "90fc1b86f7ec672657f97da961098f8c63ceeed511c32abe307f79ef1509659c", "ref_doc_id": "b3aefd5a-5a60-4bab-8962-da668c9f9fc5"}, "1f9a1918-fd27-494e-934f-82762c6719e6": {"doc_hash": "a748f4b7a806ed4f3aeacd80b7b0d345e68d0e7ca6b816ca778b41af925ed982", "ref_doc_id": "b3aefd5a-5a60-4bab-8962-da668c9f9fc5"}, "a735ae87-5856-4bac-8a41-9328a34d6600": {"doc_hash": "44ba02235985f08aa45b955290b65e8119c3a15ed675dc2b8b87515868ba86f9", "ref_doc_id": "c08937fc-e903-4f48-bb19-6d119daff916"}, "f288b346-600e-4650-ae6f-6865eea21046": {"doc_hash": "44b0632f7d40e30b4b08d2c2e905ad7ab134c7d4a39276c253219f27db073c61", "ref_doc_id": "15b9fb3b-eb73-4a12-ba17-01d77f0b9c21"}, "7f2d24db-459c-44e7-b640-64cf0d4afcdf": {"doc_hash": "7ff405bfef81cb4aea8d1c1ca0d7386522475a38d7252d8ff2c4f45e1bebbd46", "ref_doc_id": "12daa772-f893-4d04-8a90-da10d155e865"}, "08524250-c551-4e96-ab89-ea22c02f09ef": {"doc_hash": "804efe3b1948f7bc1c143ab0ca3e20ce4e52e9f0792d9d9c2860fd81d3b19441", "ref_doc_id": "12daa772-f893-4d04-8a90-da10d155e865"}, "8fa8bb7b-21c1-4ebb-9eb3-db940d249f21": {"doc_hash": "f13c7495a05fe34c8ec4d7a480ca0229d74131551a4cd034a19e1435af176562", "ref_doc_id": "c28235bd-959f-47d2-aecb-f81ceee62ef2"}, "d6d427fa-d589-42f6-8a51-a53a341c1b44": {"doc_hash": "08dd3444ecd12b0b22f0b74ec94859200feba1c1c3c44972a1978fedde536820", "ref_doc_id": "c28235bd-959f-47d2-aecb-f81ceee62ef2"}, "6fa79cc9-dd92-483d-a6d2-ba58ff14995f": {"doc_hash": "db5bf8d84b32b5e29ee0001874a1c7b1acfe0a23a6ae504a7f1b86d89b0f39d2", "ref_doc_id": "be7736d9-8aa3-4df3-bfdd-41d3c15ad776"}, "adbfc273-47a6-4b05-b69c-73991d9fedc6": {"doc_hash": "cebd0dc1ec3230b0b4c0859998b81bb515b2c4cffe81624cca5200882c526d0b", "ref_doc_id": "be7736d9-8aa3-4df3-bfdd-41d3c15ad776"}, "25fa2ce5-52da-46b5-9e68-dcaed4470947": {"doc_hash": "f2cc0baefea0e1e3d1246e2ec3d5358927f845a561214726f588ef9494407036", "ref_doc_id": "446dfa36-0794-45b9-942f-cdd0f05f6b09"}, "eee149dc-c107-4657-a3cc-08f8e133ae18": {"doc_hash": "d01ffe7e622fcb2a915660b616a7d4047dc32485ea31a66c705dcc5265faf1ba", "ref_doc_id": "446dfa36-0794-45b9-942f-cdd0f05f6b09"}, "c5ebc1a0-51ae-49ef-9997-98bee85c1d12": {"doc_hash": "4f988d6f0715795946e11c1fb78011addc04d392ccbc60829fd920a582e13961", "ref_doc_id": "036b28b7-3a22-4eaa-aeaf-f623eac2b5bd"}, "6c1a2fcd-77d9-46d0-8ec9-b7459e381a33": {"doc_hash": "3f09ceba6e9c82660046c73894e543aad2c0457a934603e61b0368c575c4d978", "ref_doc_id": "036b28b7-3a22-4eaa-aeaf-f623eac2b5bd"}, "933577b3-4bb7-402a-b64c-dc78c2dae4d3": {"doc_hash": "68740f808aa5bf200d04cd1ec6461cbb7dcd298346fca2747729727430ca6737", "ref_doc_id": "c989df6e-8dc3-4754-b2a1-c5bcdfabe0e4"}, "76017ac8-7bd7-47e3-9183-9e63d8547257": {"doc_hash": "9dd8c2a6e01949a06061179a7c73a36f44652fbadd4538888a61e02ba0e67862", "ref_doc_id": "c989df6e-8dc3-4754-b2a1-c5bcdfabe0e4"}}, "docstore/ref_doc_info": {"0aedb42c-40a9-4e23-ae4d-6349762fd4ae": {"node_ids": ["d7c8fdab-09be-4f44-8b48-7097025cbefe", "8d66aba3-781b-4f65-9789-4c0d52d205c5"], "metadata": {"page_label": "1", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "b831dd29-def8-47cb-ae7c-a20123db8836": {"node_ids": ["6e076a90-493a-462f-a532-92b9a044b5b1", "200941cd-78f6-4e4a-9e32-ee17811558d0"], "metadata": {"page_label": "2", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "081e806b-0489-4f0a-824d-f759cfec0321": {"node_ids": ["606b603e-0be4-41d6-a28a-e0a3f8642be3"], "metadata": {"page_label": "3", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "76848cfd-028d-4b50-b0a1-7dfdf6feb893": {"node_ids": ["30f08385-9974-435a-aeec-d28425c18c4e"], "metadata": {"page_label": "4", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "a62a1bc9-e80e-4dd8-9f88-2d7d4bff63a5": {"node_ids": ["c1d209c4-8132-4cbd-9ea6-90c8b1f8c5ed"], "metadata": {"page_label": "5", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "306caaa3-2674-4c00-a625-ee0abca82678": {"node_ids": ["c989c2c9-e961-45a3-b871-14cf0e2906c4", "059a7f70-4a8a-4d82-ac8d-e6abad27510a"], "metadata": {"page_label": "6", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "4c695a13-8013-42b2-ac4d-90a6443e5881": {"node_ids": ["5c5d0ff4-6a3b-4039-99d5-f188e6fa1281", "fe1b3b08-1b5d-49b2-ba35-f8b9e30406d7", "1f9530ce-d89f-4c87-9d47-d1a26969abf6"], "metadata": {"page_label": "7", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "13682a38-9c55-46cf-b46c-68a644d4a2fc": {"node_ids": ["1ecb6cb2-e7dd-4680-9233-fc83d5b5da8b", "dd9cedc5-6eec-4e8d-a91f-48eae517fee7", "1bb4d472-fc1a-450d-b588-eda53e5f3f02"], "metadata": {"page_label": "8", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "b3aefd5a-5a60-4bab-8962-da668c9f9fc5": {"node_ids": ["acecd13e-28ee-49a8-862d-cd7cfb6a2972", "1f9a1918-fd27-494e-934f-82762c6719e6"], "metadata": {"page_label": "9", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "c08937fc-e903-4f48-bb19-6d119daff916": {"node_ids": ["a735ae87-5856-4bac-8a41-9328a34d6600"], "metadata": {"page_label": "10", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "15b9fb3b-eb73-4a12-ba17-01d77f0b9c21": {"node_ids": ["f288b346-600e-4650-ae6f-6865eea21046"], "metadata": {"page_label": "11", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "12daa772-f893-4d04-8a90-da10d155e865": {"node_ids": ["7f2d24db-459c-44e7-b640-64cf0d4afcdf", "08524250-c551-4e96-ab89-ea22c02f09ef"], "metadata": {"page_label": "12", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "c28235bd-959f-47d2-aecb-f81ceee62ef2": {"node_ids": ["8fa8bb7b-21c1-4ebb-9eb3-db940d249f21", "d6d427fa-d589-42f6-8a51-a53a341c1b44"], "metadata": {"page_label": "13", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "be7736d9-8aa3-4df3-bfdd-41d3c15ad776": {"node_ids": ["6fa79cc9-dd92-483d-a6d2-ba58ff14995f", "adbfc273-47a6-4b05-b69c-73991d9fedc6"], "metadata": {"page_label": "14", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "446dfa36-0794-45b9-942f-cdd0f05f6b09": {"node_ids": ["25fa2ce5-52da-46b5-9e68-dcaed4470947", "eee149dc-c107-4657-a3cc-08f8e133ae18"], "metadata": {"page_label": "15", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "036b28b7-3a22-4eaa-aeaf-f623eac2b5bd": {"node_ids": ["c5ebc1a0-51ae-49ef-9997-98bee85c1d12", "6c1a2fcd-77d9-46d0-8ec9-b7459e381a33"], "metadata": {"page_label": "16", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}, "c989df6e-8dc3-4754-b2a1-c5bcdfabe0e4": {"node_ids": ["933577b3-4bb7-402a-b64c-dc78c2dae4d3", "76017ac8-7bd7-47e3-9183-9e63d8547257"], "metadata": {"page_label": "17", "file_name": "Chap30.pdf", "file_path": "ContentPDFs\\Chap30.pdf", "file_type": "application/pdf", "file_size": 1105115, "creation_date": "2024-03-21", "last_modified_date": "2024-03-21", "last_accessed_date": "2024-03-21"}}}}